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Preamble
Granting clinical staff privileges to physicians is the
primary mechanism institutions use to uphold quality care.
The Joint Commission requires that medical staff privi-
leges be based on professional criteria speciﬁed in medical
staff bylaws. Physicians themselves are charged with
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359deﬁning the criteria that constitute professional compe-
tence and with evaluating their peers accordingly. The
process of evaluating physicians’ knowledge and compe-
tence has become more complex as various subspecialties
have evolved over time.
The American College of Cardiology Foundation
(ACCF)/American Heart Association (AHA)/American
College of Physicians (ACP) Task Force on Clinical
Competence and Training was formed in 1998 to develop
recommendations for attaining and maintaining the
cognitive and technical skills necessary for the competent
performance of a speciﬁc cardiovascular service, procedure,
or technology. These documents are evidence based, and
where evidence is not available, expert opinion is used to
formulate recommendations. Indications for and contra-
indications to speciﬁc services or procedures are not
included in the scope of these documents. Recommenda-
tions are intended to assist those who must judge the
competence of cardiovascular healthcare providers entering
practice for the ﬁrst time and/or those in practice under-
going periodic review of their expertise. The assessment of
competence is complex and multidimensional; therefore,
isolated recommendations contained herein may not
necessarily be sufﬁcient or appropriate for judging overall
competence. The current document addresses competence
in coronary-based cardiovascular interventional procedures
and is authored by representatives of the ACCF, the
AHA, and the Society for Cardiovascular Angiography
and Interventions (SCAI). This document applies to
specialists trained in internal medicine and adult cardiology
and is not meant to be a clinical competence statement on
procedures for congenital heart disease in the child or
young adult.
To avoid actual, potential, or perceived conﬂicts of
interest that may arise as a result of industry relationships or
personal interests among the writing committee, all
members of the writing committee, as well as peer reviewers
of the document, are asked to disclose all current healthcare-
related relationships, including those existing 12 months
before initiation of the writing effort. The ACCF/AHA/
ACP Task Force on Clinical Competence and Training
reviews these disclosures to determine what companies
make products (on market or in development) that pertain
to the document under development. Based on this infor-
mation, a writing committee is formed to include a majority
of members with no relevant relationships with industry or
other entity (RWI), led by a chair with no relevant RWI.
Authors with relevant RWI are not permitted to draft or
vote on text or recommendations pertaining to their RWI.
RWI is reviewed on all conference calls and updated as
changes occur. Author and peer reviewer RWI pertinent to
this document are disclosed in Appendices 1 and 2,
respectively. Additionally, to ensure complete transparency,
authors’ comprehensive healthcare-related disclosure informa-
tiondincluding RWI not pertinent to this documentdis
available online (see Comprehensive RWITable). Disclosureinformation for the ACCF/AHA/ACP Task Force on
Clinical Competence and Training is also available online
at http://www.cardiosource.org/ACC/About-ACC/Who-
We-Are/Leadership/Guidelines-and-Documents-Task-
Forces.aspx, as well as the ACCF disclosure policy for
document development at http://www.cardiosource.org/
Science-And-Quality/Practice-Guidelines-and-Quality-
Standards/Relationships-With-Industry-Policy.aspx.
The work of the writing committee was supported
exclusively by the ACCF without commercial support.
Writing committee members volunteered their time to this
effort. Conference calls of the writing committee were
conﬁdential and attended only by committee members.
Jonathan L. Halperin, MD, FACC, FAHA
Chair, ACCF/AHA/ACP Task Force on Clinical
Competence and Training
1. Introduction
Physician competence is an essential component in the
provision of optimal health care. Physicians must have the
appropriate training, fund of knowledge, clinical decision
making, and technical skills to deliver their services in
a competent and caring manner. Healthcare systems and
payers also expect optimal care delivered in an efﬁcient and
cost-sensitive manner. In formulating conclusions and
recommendations, it is important to emphasize that the
ultimate goal of setting standards is to facilitate the
attainment of optimal patient outcomes. Optimal outcome
is most likely when operators select clinically appropriate
patients for interventional procedures and perform these
procedures at a requisite level of proﬁciency and compe-
tency. Institutional and programmatic quality is ultimately
determined by its success in achieving that goal.
This document is an update of the 2007 ACCF/AHA/
SCAI Clinical Competence Statement on Cardiac Inter-
ventional Procedures (1). The operator and institutional
volume discussion, conclusions, and recommendations in
this document supersede the recommendations in the 2011
ACCF/AHA/SCAI Guideline on Percutaneous Coronary
Intervention (PCI) (2). Although the 2011 PCI guideline
includes recommendations regarding operator and insti-
tutional volume, it was anticipated that this current writing
committee, tasked speciﬁcally with examining volume
thresholds, would be the primary source and that the PCI
guidelines would be subsequently modiﬁed.
1.1. Document Development Process
1.1.1. Writing Committee Organization
The writing committee consisted of a broad range of
members representing 3 societies, identiﬁed on the basis of
1 or more of the following attributes: PCI operators with
experience in various clinical settings (e.g., private practice,
hospital-based, and academic settings; high-, medium-,
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360and low-volume operators; small, medium, and large
catheterization labs; hybrid labs; and labs with and without
surgical backup); physicians experienced in both radial
and femoral access; physicians with broad clinical experi-
ence who have had considerable previous involvement
with PCI; physicians with expertise in systems of care
for patients presenting with acute myocardial infarction;
a cardiac surgeon; cardiovascular training program direc-
tors; catheterization laboratory directors with experience
managing a broad cross section of interventional operators;
general cardiologists; quality assurance experts; and clinical
researchers who have studied PCI outcomes. This writing
committee met the College’s disclosure requirements for
relationships with industry as described in the Preamble.
1.1.2. Document Development and Approval
The writing committee convened by conference call and
email to ﬁnalize the document outline, develop the initial
draft, revise the draft per committee feedback, and ulti-
mately, sign off on the document for external peer review.
The ACCF, AHA, and SCAI participated in peer review,
resulting in 36 reviewers representing 316 comments.
Comments were reviewed and addressed by the writing
committee. A member of the ACCF/AHA/ACP Task
Force on Clinical Competence and Training served as lead
reviewer to ensure that all comments were addressed
adequately. Both the writing committee and task force
approved the ﬁnal document to be sent for Board review.
The ACCF Board of Trustees, AHA Science Advisory
and Coordinating Committee, and the SCAI Board of
Trustees reviewed the document, including all peer review
comments and writing committee responses, and approved
the document in April 2013. This document is considered
current until the Task Force on Clinical Competence and
Training revises or withdraws it from publication.
1.2. Purpose of This Document
This document was developed to review the currently
available scientiﬁc data with the following purposes:
1. To characterize the expected success and complica-
tion rates for coronary artery interventional proce-
dures when performed by skilled operators.
2. To identify comorbidities and other risk factors that
may be used for risk adjustment when assessing
procedure-speciﬁc expected success and complica-
tion rates.
3. To assess the relationship between operator activity
level and success rates in PCI procedures as assessed
by risk-adjusted outcome statistics.
4. To assess the relationship between institutional
activity level and success rates in PCI procedures as
assessed by risk-adjusted outcome statistics.
5. To develop recommendations for assessment of
operator proﬁciency and institutional program
quality, including data collection to permitmonitoring of appropriateness and effectiveness of
PCI procedures both at the level of the operator and
the institution.
6. To assess the use of coronary procedures in patients
with structural disease.
This document addresses coronary-based interventions in
the adult and does not address procedures for non–coro-
nary-based interventions involving structural heart disease
in the child or adult.2. Percutaneous Coronary Interventions
2.1. Evolution of Competence
and Training Standards
PCI has become a widely practiced and integral compo-
nent of cardiovascular therapy. The subspecialty has
evolved into treating a wide range of both stable and
acutely ill patients presenting with a broad spectrum, not
only of increasingly complex coronary artery disease, but
also of other cardiovascular conditions. The range and
complexity of the equipment, adjunctive techniques, and
ancillary components used to perform PCI (along with the
clinical settings in which it is utilized, e.g., elective and
acute coronary disease; native vessel and venous bypass;
and lesion location and characteristics) have also evolved
dramatically. Coincident with this has been recognition of
the specialized knowledge and technical skills required
to perform PCI, and the critical roles of formalized
training, continuing education, and outcomes monitoring.
Formal interventional cardiology training programs were
ﬁrst organized in the 1980s; and in 1999, the American
Board of Internal Medicine (ABIM) offered its ﬁrst
examination for added certiﬁcation in Interventional
Cardiology. Currently, eligibility to qualify for this exam-
ination requires board certiﬁcation in general cardiology,
and successful completion of a 1-year dedicated interven-
tional cardiology fellowship, in a program accredited by the
Accreditation Council of Graduate Medical Education
(ACGME). In 2012 to 2013, there were 141 ACGME-
accredited programs in Interventional Cardiology, with
319 enrolled fellows. The current ACGME program and
educational requirements for interventional cardiology
were published in 2007; new/updated requirements
became effective in July 2012 (3). The ACCF has further
contributed to the deﬁnition of training standards and
recommendations via its Adult Cardiovascular Medicine
Core Cardiology Training (COCATS) documents (4).
During the past several years, there has also been a move
toward a more structured deﬁnition of competency-based
requirements and training. This includes the use of the
6 competency domains promulgated by the ACGME, and
adopted and endorsed by the ABIM (medical knowledge;
patient care and procedures; practice-based learning;
systems-based practice; interpersonal and communication
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361skills; and professionalism). This format is also increasingly
utilized, not only for training programs, but also for
demonstration of maintenance of competency for prac-
ticing physicians. ACCF has also adopted this format as
part of its training and lifelong learning competency
documents, and has developed tools and programs to assist
physicians in assessing, enhancing, and documenting
competency. Section 2.7 of this document depicts core
competency components of PCI utilizing this structure. A
key characteristic of a competency-based system is the use
of outcomes-based evaluations. For training programs, the
evaluation tools, for example, include direct observation by
instructors, as well as in-training examination, procedure
logbooks/portfolios, and simulation. For practicing physi-
cians, the maintenance of the competencies can include,
for example, physician-speciﬁc data from registries (e.g.,
ACCF–National Cardiovascular Data Registry [NCDR])
as well as from hospital databases and quality programs,
along with maintenance of certiﬁcation (MOC) and
continuing medical education (CME). The competency
framework includes deﬁnitions of competency components
and potential evaluation tools related to an individual’s
practice-based learning, as well as skills related to working
effectively in healthcare systems, communication with
patients and other members of the healthcare team, and
professionalism (see Section 2.7).
2.2. Evolution of Coronary Interventional
Capabilities
Andreas Gruentzig pioneered the ﬁeld of coronary inter-
vention with the ﬁrst coronary balloon angioplasty in
1977 (5,6). During the past 35 years, the ﬁeld has rapidly
expanded. The evolution of the cognitive and technical
knowledge base for proﬁciency in PCI has paralleled the
advancements in interventional equipment and the broad-
ening of clinical and angiographic indications for PCI.
Although the basic structure of coronary balloons and
atherectomy devices has not changed substantially over
the years, the development of the coronary artery stent
dramatically altered the practice of coronary intervention.
The initial stents available markedly reduced the need
for PCI-related emergency coronary bypass surgery (7),
and drug-eluting stents have substantially lowered the
occurrence of restenosis and the need for repeat revascu-
larization following PCI (8). These technical innovations
continue to evolve at a rapid pace, with new devices on
the horizon (9,10). These advances come with the respon-
sibility that the interventional cardiologist acquires the
technical and cognitive skills necessary to use these emerging
devices optimally to provide the best outcomes for their
patients.
In tandem with these technical developments, the use of
PCI has expanded to more complex lesion subsets such
as chronic total occlusions, left main stenosis, and bifur-
cation lesions (11). These unmet needs spurred industry to
produce an expanding selection of specialized devices (e.g.,balloons, catheters, wires, and dedicated stents) to facilitate
successful procedure completion. Similar to the evolution
in the device ﬁeld, pharmacological advances have con-
tinued at a robust pace, contributing to the increased
clinical beneﬁt appreciated by patients in recent years (12).
These advances most notably involving antithrombotic and
antiplatelet agents require the interventional cardiologist
to have a solid working knowledge of the pharmacoki-
netics, indications, contraindications, and optimal timing
of long-term monitoring of these drugs (13,14). New oral
antithrombin and anti-Xa agents are emerging, which
require further understanding of their indications and
side effects.
The recognition that coronary angiography provides an
imperfect assessment of coronary structure and stenosis
severity has led to new imaging modalities such as intra-
vascular ultrasound, optical coherence tomography, and near
infrared spectroscopy (15). Assessment of the intermediate-
severity stenosis based on the coronary angiogram alone has
always been challenging. Following publication of the
FAME (Fractional Flow Reserve Versus Angiography
for Multivessel Evaluation) trial (16), functional testing of
angiographic intermediate coronary stenosis with measure-
ment of the fractional ﬂow reserve is now increasingly rec-
ommended when noninvasive evidence of ischemia is
absent before considering revascularization of such lesions.
Furthermore, the FAME 2 trial demonstrated that a frac-
tional ﬂow reserve–guided PCI strategy in patients with
stable angina improves outcome beyond that of optimal
medical therapy, particularly with regard to reduction of
repeat hospitalization for coronary ischemia (17). The
correct application of all these new devices requires
continued expansion of both cognitive and procedural skill
sets by the practicing interventional cardiologist.
Finally, the increasing complexity of PCI in patients
with poor cardiac reserve has encouraged the development
of several percutaneous left ventricular support devices
(18). Insertion and monitoring of these devices necessitates
a solid understanding of cardiovascular hemodynamics. In
summary, the evolution of the ﬁeld of interventional
cardiovascular medicine has, and will continue, to require
an unwavering commitment from the physician commu-
nity to maintain excellence through lifelong learning.
2.3. Procedural Success and Complications of
Coronary Interventional Procedures
2.3.1. PCI Success
PCI success can be deﬁned using angiographic, procedural,
and clinical variables. Factors associated with increased
success and decreased complication rates include improve-
ments in equipment (e.g., balloon catheters, guide cathe-
ters, guidewires), coronary stents (bare-metal stents and
drug-eluting stents), embolization protection, aspiration
thrombectomy devices, and advances in adjunctive phar-
macotherapy (2,19–23).
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362Historically, angiographic success for balloon angio-
plasty has been deﬁned as a reduction of minimum percent
diameter stenosis to <50% with Thrombolysis In
Myocardial Infarction (TIMI) grade 3 ﬂow and without
side branch loss, ﬂow-limiting dissection or angiographic
thrombus. For coronary stents, a minimum percent dia-
meter stenosis of <20% was the previous angiographic
benchmark of an optimal result (24,25). However, with
current stents and the recognized importance of adequate
stent deployment (26,27), the 2011 ACCF/AHA/SCAI
PCI guideline suggests a minimum percent diameter
stenosis of <10% (or optimally as close to 0% as possible)
as the new angiographic benchmark for stent results (2). In
addition, following the conclusion of a successful proce-
dure, there should be TIMI grade 3 ﬂow and no occlusion
of a signiﬁcant side branch, ﬂow-limiting dissection, distal
embolization, or angiographic thrombus.
Procedural success is deﬁned as angiographic success
without in-hospital major complications such as death,
myocardial infarction (MI), stroke, and emergency coro-
nary artery bypass graft (CABG) surgery. The deﬁni-
tion of PCI-related MI has evolved over time, and the
current deﬁnition is provided below in Section 2.3.2
(2,24,25,28–30).
Short-term clinical success includes angiographic and
procedural success with the subsequent relief of signs
and/or symptoms of myocardial ischemia. Long-term
clinical success requires that the relief of myocardial
ischemia remain durable, persisting for more than 1 year
after the procedure (2). The most common reason for
a failure of long-term clinical success has been restenosis.
Stent thrombosis is an uncommon, but an important, cause
of short- and long-term clinical failure.
2.3.2. PCI Complications
PCI complications were reviewed comprehensively in
the 2011 ACCF/AHA/SCAI PCI guideline (2). Major
PCI-related complications include death, MI, emergency
CABG surgery, and stroke, commonly denoted as
MACCE (major adverse cardiovascular and cerebrovas-
cular events). Other important complications include
vascular complications (e.g., pseudoaneurysm, arteriove-
nous ﬁstula, retroperitoneal bleeding, clinically overt
atheroembolism), any major bleeding, and contrast
nephropathy. The incidence of in-hospital mortality for
PCI, determined from the NCDR CathPCI database
between 2004 and 2007, was 1.27%, ranging from 0.65%
in elective procedures to 4.81% for PCI performed in the
setting of ST-elevation myocardial infarction (STEMI)
(31). However, an important perspective is provided
from a large contemporary single-center series reporting
an overall mortality of approximately 1%, but with half of
all deaths due to primarily noncardiac causes (32). The
incidence of PCI-related MI depends on the criteria
used to deﬁne MI. The clinical signiﬁcance of “enzy-
matically deﬁned” MIs in the absence of clinical orangiographic correlates has been controversial. The third
iteration of the ESC/ACCF/AHA/WHF Task Force
for the Universal Deﬁnition of Myocardial Infarction
now requires for the diagnosis of PCI-related MI (“type
4a”) both: 1) elevation of troponin (>5  99th percentile
upper reference limit in patients with normal baseline
values or a rise in troponin values >20% if the baseline
values are elevated and stable or falling); and 2) either
symptoms suggestive of myocardial ischemia, or new
ischemic echocardiographic (ECG) changes (or new left
bundle-branch block), or angiographic evidence of
PCI complication, or imaging demonstrating new loss
of viable myocardium (30). The need for emergency
CABG surgery for a failed PCI has decreased dramati-
cally especially since the introduction of coronary artery
stents noting an incidence of 0.4% reported from the
NCDR database from 2004 to 2006 (33). The inci-
dence of PCI-related stroke is also low at 0.22%;
however, in-hospital mortality for these patients is quite
high, reported to be 25% to 30% (34,35). Finally, it has
been recently appreciated that periprocedural bleeding is
associated with increased mortality, and accordingly,
strategies to avoid bleeding are continuing to be devel-
oped (36,37). Factors reported to be associated with an
increased risk of bleeding include advanced age, low
body mass index, chronic kidney disease, baseline ane-
mia, excessive platelet and/or thrombin inhibition, non-
compressible vascular access site, and larger sheath size
(2,38,39).
2.4. Patient and Lesion Variables Inﬂuencing
Success and Complication Rates
Patient characteristics associated with an increased risk of
adverse outcome include advanced age, diabetes, chronic
kidney disease, heart failure, multivessel disease, clinical
presentation with an acute coronary syndrome (non-
STEMI or STEMI), and cardiogenic shock (31,40–42).
Lesion-related characteristics associated with increased
complications and/or lower procedural success include
lesion length, thrombus, degenerated saphenous vein
grafts, and chronic total occlusions (40,43). With advances
in PCI technology, lesion morphology may be currently
less predictive of procedural complications compared with
the past (44).
The most widely accepted model to predict PCI
mortality is the NCDR CathPCI Risk Score system
(Table 1), which utilizes multiple variables to predict
inpatient mortality (2,31). This model performs very
well (C statistic: approximately 0.90), although the
predictive capability decreases in high-risk patients.
Consideration of certain general and neurological
patient factors in addition to NCDR variables
improves the predictive value of the model (32).
Consideration of “compassionate use” features (coma on
presentation, active hemodynamic support during PCI,
and cardiopulmonary resuscitation at PCI initiation) has
Table 1. The NCDR CathPCI Risk Score System
Variable Scoring Response Categories Total Points Risk of In-Patient Mortality
Age <60 60, <70 70, <80 80 0 0.00%
0 4 8 14 5 0.10%
Cardiogenic shock No Yes 10 0.10%
0 25 15 0.20%
Prior CHF No Yes 20 0.30%
0 5 25 0.60%
Peripheral vascular disease No Yes 30 1.10%
0 5 35 2.00%
Chronic lung disease No Yes 40 3.60%
0 4 45 6.30%
GFR <30 30–60 60–90 >90 50 10.90%
18 10 6 0 55 18.30%
NYHA functional class IV No Yes 60 29.00%
0 4 65 42.70%
PCI status (STEMI) Elective Urgent Emergent Salvage 70 57.60%
12 15 20 38 75 71.20%
PCI status (no STEMI) Elective Urgent Emergent Salvage 80 81.00%
0 8 20 42 85 89.20%
90 93.80%
95 96.50%
100 98.00%
Reprinted with permission from Peterson et al. (31).
CathPCI indicates catheterization percutaneous coronary intervention; CHF, congestive heart failure; GFR, glomerular ﬁltration rate; NCDR, National Cardiovascular Data Registry; NYHA, New York
Heart Association; and STEMI, ST-elevation myocardial infarction.
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the model (45). Models to predict procedural success
include the modiﬁed ACC/AHA score (40) and the
SCAI score (46,47) (Table 2), with good to very goodTable 2. The SCAI Lesion Classiﬁcation System
Type I lesions (highest success expected, lowest risk)
1. Does not meet criteria for C lesion
2. Patent
Type II lesions
1. Meets any of these criteria for ACC/AHA C lesion
Diffuse (>2 cm length)
Excessive tortuosity of proximal segment
Extremely angulated segments, >90 degrees
Inability to protect major side branches
Degenerated vein grafts with friable lesions
2. Patent
Type III lesions
1. Does not meet criteria for C lesion
2. Occluded
Type IV lesions
1. Meets any of these criteria for ACC/AHA C lesion
Diffuse (>2 cm length)
Excessive tortuosity of proximal segment
Extremely angulated segments, >90 degrees
Inability to protect major side branches
Degenerated vein grafts with friable lesions
Occluded for >3 months
2. Occluded
Reprinted with permission from Krone et al. (47).
ACC indicates American College of Cardiology; AHA, American Heart Association; CME,
continuing medical education; ECG, electrocardiographic; MOC, maintenance of certiﬁcation;
PCI, percutaneous coronary intervention; SCAI, Society for Cardiovascular Angiography and
Interventions; and STEMI, ST-elevation myocardial infarction.discrimination (C statistic: 0.70 to 0.82). More recently,
the SYNTAX (Synergy Between Percutaneous Coronary
Intervention with TAXUS and Cardiac Surgery) score,
which is based on an angiographic calculation, has been
shown to have value determining which patients with
unprotected left main or multivessel disease undergoing
PCI are at greatest risk for long-term major adverse
cardiac events (MACE) (48–50). There are similar
models available that help predict bleeding in patients
with acute coronary syndromes undergoing PCI. Best
treatment option proposals are facilitated by the heart
team approach endorsed as a Class I recommendation
by the ACCF, AHA, Society of Thoracic Surgeons
(STS), and American Association for Thoracic Surgery
(AATS), particularly when addressing complex patients
and/or coronary anatomy. An operator should be
familiar with the concepts of anatomical and clinical risk
to facilitate optimal clinical decision making when rec-
ommending a revascularization strategy for an individual
patient.2.5. Institutional Characteristics Related to
Procedural Success and Complication Rates
2.5.1. Impact of the Facility on Procedural Success
Physical facility requirements. Characteristics of the
physical facility in which interventional procedures are
performed have important inﬂuences on achieving
procedural success. The facility must provide the
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support equipment to enable operators to perform in the
safest and most effective environment. The real-time
ﬂuoroscopic and acquired image quality must be
optimal to facilitate accurate catheter and device place-
ment and facilitate the correct assessment of procedural
results. Physiological monitoring equipment must provide
continuous, accurate information about the patient’s
condition. Access to other diagnostic modalities such as
intravascular ultrasound and fractional ﬂow reserve should
be available. Hemodynamic support devices such as intra-
aortic balloon pumps and percutaneous ventricular assist
devices should be available in institutions routinely per-
forming high-risk PCI. These requisite support equipment
must be available and in good operating order to respond to
emergency situations (51).
Overall institutional system requirements. The
interventional laboratory must have a support system of
speciﬁcally trained laboratory personnel. Access to (or
a detailed plan to access) cardiothoracic surgical, respi-
ratory, and anesthesia services should be available to
respond to emergency situations in order to minimize
detrimental outcomes (51). The ACCF/AHA/SCAI
PCI guideline supports the heart team approach to
revascularization for high-risk complex patients (2). The
institution should have systems for credentialing,
governance, data gathering, and quality assessment.
Prospective, unbiased collection of key data elements on
all patients and consistent timely feedback of results to
providers brings important quality control to the entire
interventional program and is critical to assessing and
meeting Appropriate Use Criteria for coronary revascu-
larization (52). The 2011 ACCF/AHA/SCAI PCI
guideline update (2) recommends that:
 Primary PCI (PPCI) is reasonable in hospitals
without onsite cardiac surgery, provided that appro-
priate planning for program development has been
accomplished (Class IIa) (53,54).
 Elective PCI might be considered in hospitals with-
out onsite cardiac surgery, provided that appro-
priate planning for program development has been
accomplished and rigorous clinical and angiographic
criteria are used for proper patient selection (Class
IIb) (54–56).
 Primary or elective PCI should not be performed in
hospitals without onsite cardiac surgery capabilities
without a proven plan for rapid transport to a cardiac
surgery operating room in a nearby hospital or
without hemodynamic support capability for transfer
(Class III).
2.6. Strategies for Risk Stratiﬁcation and
Operator Evaluation
Large prospective and retrospective databases involving
patients undergoing PCI have identiﬁed clinical andangiographic characteristics that correlate with procedural
success, in-hospital morbidity, and mortality (57–59).
These observations have been used to develop multivariate
logistic regression models that can stratify patients before
the procedure and also predict outcomes based on events
during the procedure.
Risk stratiﬁcation is not perfect and is frequently
developed from a large population analysis and must
then be validated prospectively in robust clinical data
sets. Reliability of the model is best assessed by relative
predictive accuracy (C statistic: moderate is >0.80,
excellent is >0.90) and scaling accuracy (the Hosmer-
Lemeshow statistic). Several models predict periproce-
dural mortality with C statistic >0.80. Efforts are
underway to formulate periprocedural bleeding and
postprocedural contrast-induced nephropathy models
(60–62).
Model utility also must consider the frequency and
clinical importance of the event measured. Very infre-
quent events, even if severe, may not allow adequate
evaluation of operators with low volume. Results of
several years of experience must be considered to have
a sufﬁcient number of events to support statistical validity
without excessively large conﬁdence intervals. Operators
and catheterization laboratories should be strongly en-
couraged to submit information to large and transparent
clinical databases that allow for adequate benchmarking
and the development of contemporary risk-adjusted
outcomes. Comparison of operator outcomes should be
only 1 component of a comprehensive continuous quality
improvement program at a facility.
2.7. Components of Operator Competence
Table 3 identiﬁes the components of operator compe-
tence for PCI utilizing the ACGME core competency
structure (see Section 2.1). Included in each of the
sections are potential tools for evaluation and outcome
assessment.
2.7.1. ABIM Certiﬁcation
Although ABIM-IC certiﬁcation and MOC are stron-
gly recommended, it is recognized that for some indi-
viduals not eligible for ABIM certiﬁcation because their
training was obtained outside the United States, alter-
native tools may be acceptable. Interventional cardiolo-
gists should also attain at least 30 hours of CME every
2 years.
2.8. Relationships of Institutional and
Operator Experience and Activity to Outcomes in
Coronary Interventional Procedures
Since the original observation by Luft et al. (63) in 1979
showing fewer deaths among patients undergoing
procedures at higher-volume hospitals, the interplay of
volume and outcome has been the subject of much
investigation. In 1988, the ACC and AHA ﬁrst adopted
Table 3. Core Competency Components for Percutaneous Coronary Interventions
Medical Knowledge
1. Know normal coronary artery anatomy, its variations and congenital abnormalities, and the physiology of coronary/
myocardial blood ﬂow.
2. Know the pathology of atherosclerotic and nonatherosclerotic coronary diseases.
3. Know the causes, pathophysiology, and differential diagnosis of myocardial ischemia and infarction.
4. Know the pathophysiology, clinical characteristics, and management of PCI-related spasm, slow reﬂow, abrupt
closure, and restenosis.
5. Know the structural and polymer characteristics of coronary stents and drugs incorporated into them.
6. Know the coagulation cascade, and the indications, risks, and clinical pharmacology of antiplatelet, anticoagulant,
and ﬁbrinolytic drugs used in conjunction with, or in place of, PCI.
7. Know the indications for PCI and the adjunctive and alternative uses of medical therapy and surgery for patients with
coronary artery disease.
8. Know the methods to assess functional signiﬁcance of coronary lesions in the catheterization laboratory.
9. STEMI: know the roles of time of presentation, facility capability, anticipated door-to-device time, presence or
absence of ongoing symptoms, and ECG abnormalities on the selection of reperfusion strategy.
10. Know the signs and hemodynamics of cardiac dysfunction, and their impact on reperfusion strategy and PCI
decisions.
11. Know the limitations and contraindications of PCI, particularly as these relate to comorbid systemic diseases and
special anatomical subsets.
12. Know the specialized equipment, techniques, and devices used to perform PCI, including, but not limited to:
 X-ray imaging, radiation safety, and measures to minimize radiation exposure of patients, operators, and staff.
 Specialized catheterization recording and safety equipment (physiological data recorders, pressure transducers,
blood gas analyzers, deﬁbrillators).
 Catheters, guidewires, balloon catheters, stents, atherectomy devices, ultrasound catheters, intra-aortic balloon
pumps, puncture site sealing devices, contrast agents, distal protection devices, and thrombus extraction
devices.
13. Know the risk factors for, and the signs and management of, major PCI procedural complications
and bleedingdincluding coronary vascular (e.g., dissection, thrombosis, perforation, embolization), and
other vascular (e.g., pseudoaneurysm, retroperitoneal hemorrhage, arteriovenous ﬁstula, and stroke)
complications.
Know the systemic complications of PCI, including acute pulmonary congestion and contrast-related nephropathy, along
with mechanisms to reduce their risk of occurrence.
Evaluation Tools: ABIM-IC certifying examination; ABIM-IC MOC (see Section 2.7.1); accredited CME.
Patient Care and Procedures
1. Skill to integrate clinical and laboratory data in selecting appropriate candidates for PCI, incorporating evidence-based
guideline and clinical trial information.
2. Skills to perform percutaneous arterial (femoral and brachial/radial) and venous access, including postprocedural
management and appropriate use of closure devices.
3. Skills to perform and analyze coronary angiograms, assess functional signiﬁcance of coronary lesions, and determine
risk/beneﬁt of PCI (and the type of PCI) versus alternative revascularization or medical treatments.
4. Skills to effectively and safely operate and manipulate intravascular guidewires, coronary angioplasty balloon cath-
eters, atherectomy devices, and coronary stents.
5. Skill to appropriately select and utilize intracoronary ultrasound, Doppler ﬂow wires, and pressure wires.
6. Achievement of volume and quality outcome benchmarks for PCIdin training and in practice.
7. Skills to promptly detect and treat complications of PCIdboth in the laboratory and postprocedure.
8. Skills to promptly recognize, identify cause of, and treat hemodynamic instability, including the appropriate emergent
use of pharmacological agents and/or percutaneous mechanical circulatory assist devices.
9. Skills to carry out postprocedural evaluation, establish medical regimen and subsequent outpatient follow-up; including
appropriate use of follow-up outpatient testing.
Evaluation Tools: ABIM-IC certiﬁcation; direct observation; professional society (ACCF) registries; hospital quality
programs; conference participation.
Continued on the next page
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transluminal coronary angioplasty (PTCA) case/week to
maintain proﬁciency (64). The ﬁrst Clinical Competence
Statement on PTCA was subsequently published in
1990 by the ACP/ACC/AHA Task Force on ClinicalPrivileges in Cardiology and advocated a minimum of
75 PTCA procedures/year to maintain continuing
competence (65). Since then, the use of PCI volume as
a surrogate for quality and the adoption of arbitrarily-
deﬁned annual volume standards, despite the lack of
Table 3. Continued
Practice-Based Learning and Improvement
1. Review personal outcomes data via registry and/or hospital quality monitoring programs to identify and carry out
areas of focused education or quality initiative.
2. Attend at least 30 hours of PCI CME every 2 years (this may include participation in the hospital’s CME-approved
multidisciplinary catheterization conference).
3. Participate in PCI quality programs of the hospital, including review of major complications.
4. Carry out structured education regarding new technologies and procedures.
Evaluation Tools: Professional society registry data; hospital/catheterization lab quality data; catheterization/morbidity
and mortality conferences; simulation; ABIM-IC MOC.
Systems-Based Practice
1. Participate in regular (at least monthly) catheterization laboratory conferences, including participation by clinical
cardiologists, interventional operators, and cardiothoracic surgeons.
2. Participate in a hospital-based state, regional, or national database to measure risk-adjusted PCI
outcomes of the laboratory and compare them with regional and national benchmarks for improving quality
of care.
3. Incorporate risk/beneﬁt and cost awareness factors in clinical decisions and management of patients
undergoing PCI.
4. Effectively lead the catheterization laboratory team in the performance of the procedure and care of the patient.
5. In conjunction with the hospital, ensure that the catheterization laboratory meets the following requirements:
 Provides safe and quality radiologic, monitoring, and patient support equipment.
 Has appropriate and qualiﬁed stafﬁng.
Evaluation Tools: Multisource (360) evaluations, professional society registry outcomes data; hospital/catheterization lab
quality data.
Professionalism
1. Practice evidence-based, guideline-directed, and patient-centered care within the scope of personal technical skills
and expertise.
Evaluation Tools: Multisource evaluations; outcomes and registry data.
Interpersonal Skills and Communication
1. Communicate effectively and demonstrate sensitivity with patients across a broad socioeconomic, ethnic, and cultural
spectrum.
2. Communicate effectively and professionally (and carry out effective transition) with referring physicians and other
members of the cardiovascular team.
Evaluation Tools: Patient satisfaction data; multisource (360) evaluations.
ABIM-IC indicates American Board of Internal Medicine–Interventional Cardiology; ACCF American College of Cardiology Foundation; CME, continuing
medical education; ECG, electrocardiography; MOC, maintenance of certiﬁcation; PCI, percutaneous coronary intervention; and STEMI, ST-elevation
myocardial infarction.
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(66,67).
2.8.1. Evidence Reviewed
SEARCH STRATEGY
To compile the relevant available scientiﬁc evidence
relating institutional and operator activity level to outcomes
(Online Appendices 1 to 3), we performed a computerized
systematic literature search of all publications using
Medline (PubMed and Ovid) and Cochrane Databases
for studies published since January 1990. We also reviewed
abstracts from recent ACCF, AHA, European Society of
Cardiology, and Transcatheter Cardiovascular Therapeu-
tics (TCT) proceedings, solicited manuscripts under
review for publication from experts in the ﬁeld, and con-
ducted a manual review of the reference lists from the
available studies. Greater weight was given to recent, peer-
reviewed publications of high quality. No single work wasconsidered deﬁnitive, and the shortcomings of the
reviewed studies are discussed at length below.
2.8.1.1. RELATIONSHIP OF INSTITUTIONAL VOLUME
TO PROCEDURAL OUTCOME
We identiﬁed 17 studies examining the impact of insti-
tutional volume to outcomes of PCIs (Online Appendix 1).
Of the 8 studies conducted in the PTCA era (46,68–74),
all except 1 (68) demonstrated a relationship between
hospital volume and outcomes, with lower volume pre-
dicting predominantly the need for in-hospital CABG
surgery (6 studies) (69–74) or in-hospital mortality (4
studies) (70–73). Of the 9 studies (57,58,75–81) in the
stent era, 6 studies demonstrated an inverse relationship
between mortality and PCI volume (57,58,75,78–80); 1
study showed a decrease in 30-day and 2-year CABG
surgery in high-volume hospitals (77); and another showed
a reduction in 30-day and 1-year adjusted rates of death,
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hospitals (81). The relationship between institutional
procedural volume and outcome has been conﬁrmed by
multiple contemporary large registries, of which 3 included
>100,000 patients (58,75,78).
A recent meta-analysis examined the relation between
volume and outcome of PCI in 10 reports between 1995
and 2003 from an original pool of 140 papers (82). Of
those, 8 studies were conducted in the United States and 7
used high-quality clinical data. The ﬁnal meta-analysis
included 1,322,342 patients from 1,746 hospitals. Patients
treated in high-volume hospitals (600 PCIs/year) expe-
rienced lower in-hospital mortality (odds ratio [OR]: 0.87;
95% conﬁdence interval [CI]: 0.83 to 0.91) compared with
patients treated in lower-volume hospitals (400 to 600 PCIs
per year) (Figure 1), noting moderate heterogeneity existed.
When limiting the analyses to studies using the cutoff point
of 400 PCIs/year, heterogeneity was diminished, but the
effect estimate remained unchanged (OR: 0.86, 95% CI:
0.82 to 0.90). Interestingly, the more contemporary studies
suggested a slightly smaller effect size than earlier studies
(p ¼ 0.06); however, meta-regression did not show not-
able changes in the effect size over the years (82).
Overall, the preponderance of data suggests that hospitals
in which fewer coronary interventions are performed have
a greater incidence of adverse events, notably death and
CABG surgery for failed intervention, than hospitals per-
forming more procedures. This relation is supported by
earlier studies in the PTCA era (46,69–74), contemporary
studies in the stent era (57,58,75–81), and a recent meta-
analysis (82). The writing committee recognizes the wide
variability of institutional volume thresholds used in the
different studies and the complexity and multitude of
factors inﬂuencing PCI outcomes. However, it is impor-
tant to note that a signal exists suggesting that an institu-
tional volume threshold <200 PCIs/year appears to beFigure 1. Results of Meta-Analysis of Studies Investigating the Effe
CI indicates conﬁdence interval; and PCI, percutaneous coronary intervention. Reprinted witconsistently associated with worse outcomes across the
various studies (Online Appendix 1) (58,75,80). Full-service
(both primary and elective PCI) laboratories performing
<200 total cases annually require additional considerations.
Many such low-volume laboratories do not have onsite
surgery and were developed to provide PPCI services to
underserved or geographically isolated populations; a situa-
tion that the 2011 PCI guideline acknowledges may be
acceptable. Elective PCI is often performed in these facilities
to increase the volume of procedures and thus maintain
facility and operator proﬁciency. There are also some labo-
ratories that provide only PPCI service to similar pop-
ulations. Such facilities must have stringent systems and
process protocols with close monitoring of clinical outcomes
and additional strategies that promote adequate operator and
catheterization laboratory staff experience through colla-
borative relationships with larger-volume facilities. The con-
tinued operation of low-volume laboratories that are not
serving isolated or underserved populations should be ques-
tioned, and any laboratory that cannot maintain satisfactory
outcomes should close. This becomes increasingly relevant in
an era of declining procedural volumes and expanded care
delivery models for patients with STEMI (83).
2.8.1.2. RELATIONSHIP OF INDIVIDUAL OPERATOR VOLUME
TO PROCEDURAL OUTCOME
We identiﬁed 9 studies examining the relationship
between individual operator caseload and procedural
outcomes in the stent era (Online Appendix 2). Of these,
4 studies demonstrated the existence of a relationship
between low operator volume and increased adverse out-
comes (58,84–86), predominantly CABG, but only 1
showed a modest correlation with in-hospital mortality
(86). Notably, the 3 largest reports, each with a study
population >100,000 patients, supported the existence of
such a relationship (58,84,86).ct of Center Volume on In-Hospital Mortality After PCI
h permission from Post et al. (82).
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3,649 physicians (excluding those performing <10 PCIs/
year) from the NCDR CathPCI Registry and included
345,526 PCI procedures performed in 543 hospitals
over 4 consecutive quarters, ending in July 2009. Using
hierarchical logistic regression modeling to adjust for
patient demographics, comorbidities, cardiac status, and
hospital volume, this study compares outcomes including
in-hospital mortality of patients treated by operators who
performed <75 PCIs/year with those performing 75
PCIs/year. Median operator PCI annual volume was 75
PCIs (IQR: 38 to 127) and overall in-hospital mortality
was 1.31%. After multivariable adjustment, in-hospital
mortality remained signiﬁcantly higher among physicians
performing <75 PCIs/year (OR: 1.14; 95% CI: 1.05 to
1.24), noting that the correlation between in-hospital
mortality and operator volume was modest (R2 ¼ 0.0057),
and there was no clear inﬂection point for a minimal volume
threshold (Figure 2). The absolute difference in mortality
was 0.3% (86). Lower-volume operators had signiﬁcantly
higher rates of other complications, including bleeding,
emergency PCI, and the need for postprocedural CABG
surgery. A higher mean length of stay was also found in low-
volume operator patients. This large NCDR CathPCI
Registry analysis, representing approximately 70% to 80%
of all PCIs performed in the United States, has several
important limitations including: data are limited to only
voluntarily participating hospitals, and long-term outcome
data are not available. These ﬁndings were reported at the
2011 AHA Scientiﬁc Sessions in Orlando, Florida (86), and
the ﬁnal peer-reviewed publication is not yet available.
An earlier report by McGrath et al. (84) analyzed data
from the 1997 Medicare national claims database on
167,208 patients undergoing PCI by 6,534 operators. A
signiﬁcant relationship between operator volume and
outcome was found, noting a lower risk of post-PCIFigure 2. Scatter Plot of PCI Volume Versus In-Hospital
Mortality
PCI indicates percutaneous coronary intervention. Reprinted with permission from
Minges et al. (86).CABG surgery in patients treated by high-volume opera-
tors (>60 PCIs/year); however, there was no observed
difference in 30-day mortality (84). Similar ﬁndings were
obtained by Hannan et al. (58), who analyzed data from
107,713 PCI procedures reported in the New York State
Database from 1998 through 2000. Operator volume
thresholds were set at 75 PCIs/year on the basis of the
ACCF/AHA recommendations, and were compared with
higher levels of 100 and 125 procedures/year. There were
no differences in risk-adjusted mortality between patients
undergoing PCI performed by low- versus high-volume
operators for any of the 3 volume thresholds examined
(58). However, signiﬁcant differences for same-day and
same-stay CABG surgery were observed for all 3 volume
thresholds. For instance, patients undergoing PCI with
operators performing <75 PCIs/year had a 65% increase
of undergoing same-day CABG surgery and a 55%
increase of undergoing same-stay CABG surgery (58).
Another study by Moscucci et al. (59) involving 18,504
PCI procedures performed in 14 Michigan hospitals in
2002, demonstrated that patients treated by low-volume
operators (<90 PCIs per year) experienced a 63% in-
crease of MACE (a composite of death, MI, stroke
or transient ischemic attack, CABG surgery, and repeat
PCI) (p<0.0001) after multivariable adjustment, but not
in-hospital mortality, compared with patients treated by
operators in the higher-volume quintile. When using the
75 PCIs/year cutoff, no signiﬁcant differences in adjusted
MACE or mortality rates were observed (85).
The writing committee recognizes that the majority of
interventional cardiologists in the United States are
not achieving the previously recommended threshold of
75 PCIs annually (87). This may be related to many
factors, including but not limited to: (a) the reduction of
restenosis related to the widespread use of drug-eluting
stents; (b) improved medical therapies and increasing
appreciation of the importance of upfront guideline-
directed medical management of stable CHD; (c) the
presence of more interventional cardiologists and centers in
the United States; and (d) the development and imple-
mentation and increasing awareness of Appropriate Use
Criteria for coronary revascularization (52). We also
recognize the increased use of invasive coronary physio-
logical and anatomic assessments (e.g., fractional ﬂow
reserve, intravascular ultrasound) by many interventional
cardiologists, which are usually not counted as PCI proce-
dures but which, however, may conceivably inﬂuence
PCI volume. There is also a shift towards the performance
of noncoronary-based (structural) cardiac interventions by
many experienced high-volume operators.
Overall, it is the opinion of the writing committee that
the available evidence does not send a loud signal supporting
a consistently strong relationship between operator caseload
and mortality (58,84–86). In part, this is a function of the
extremely low procedural-related mortality that now exists
for PCI. The preponderance of data available is related to
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369clinical outcomes other than mortality and does suggest
a possible relationship between operator volume and
emergency CABG surgery and other PCI complications.
On the basis of available data and the judgment of the
writing committee involving all of these considerations, the
writing committee recommends interventional cardiologists
perform a minimum of 50 coronary interventional proce-
dures per year (averaged over a 2-year period) to maintain
competency. The writing committee acknowledges that
this number is established primarily by expert opinion
derived from the interpretation of substantial data from
multiple sources (each with inherent limitations). Because
of the limitations of these data, the writing committee
believes operators performing<50 PCIs/year should not be
denied privileges or excluded from performing coronary
interventions based solely on their procedural volume. The
committee acknowledges that there are low-volume opera-
tors who provide excellent clinical care and achieve excellent
outcomes. In instances where operators are performing<50
PCIs annually, the writing committee strongly encourages
both institutions and operators to carefully assess whether
their performance is adequate to maintain competence.
Other metrics are needed, in addition to volume and risk-
adjusted outcomes, which have very wide conﬁdence
intervals at low procedure volumes, and thus are difﬁcult
to assess accurately. The committee suggests that each
facility develop alternative pathways for the evaluation
of low-volume operators. These pathways may be estab-
lished and monitored by an independent institutional
committee (consisting of physicians and relevant healthcare
personnel) or an external review organization. The writing
committee emphasizes that volume is but 1 of several factors
that should be considered when assessing an individual
operator’s competence. Other factors to consider for
low-volume operators include (but are not limited to):
performance of additional noncoronary cardiovascular
interventional procedures, lifetime experience, ABIM
certiﬁcation in interventional cardiology, attendance at
educational symposiums, CME credits, and simulation
courses.
Although this recommendation focuses on the minimal
procedural volume considered acceptable for maintaining
competence, the writing committee believes it is impor-
tant to evaluate the performance of all operators. Sepa-
rate concerns may exist for very high-volume operators.
Compliance with suggested guidelines and appropriate-
ness of procedures are important metrics to consider
when evaluating competency of all operators.**Although the 2011 ACCF/AHA/SCAI PCI guideline includes recommendations
regarding operator and institutional volume, it was anticipated that this current
writing group, tasked speciﬁcally with examining volume thresholds, would be the
primary source and that the 2011 PCI guidelines might be subsequently modiﬁed.
Therefore, the operator and institutional volume discussion, conclusions, and
recommendations in this document supersede the recommendations in the 2011
ACCF/AHA/SCAI Guideline on Percutaneous Coronary Intervention (2).2.8.1.3. VOLUME AND OUTCOMES RELATIONSHIP FOR
PRIMARY PCI IN ACUTE MI
PPCI requires several clinical, cognitive, and procedural
skills not necessarily involved with performing elective
PCI. Online Appendix 3 summarizes 16 published studies
examining the relationship between operator and institu-
tional volume and outcomes in patients undergoing PPCI.
Of those studies, 4 showed no relationship between
volume and mortality (88–91), although the latter (the only
U.S. study of all 4 reports) demonstrated shorter door-to-
balloon (DTB) time and greater adherence to evidence-
based therapies observed in higher-volume PPCI centers
(91). Of the 12 remaining reports, 10 studies (58,92–100)
demonstrated a signiﬁcant inverse relationship between
hospital PPCI volume and in-hospital mortality, whereas 2
studies (101,102) showed similar relationships relating
hospital total PCI volume to mortality. Only 2 studies
(97,99) demonstrated a signiﬁcant inverse relationship
between the operator PPCI volume and in-hospital
mortality, whereas 1 report (58) failed to show such
a relationship after multivariable adjustment. It is impor-
tant to note that these relationships were examined nearly
exclusively at hospitals with onsite cardiac surgery.
Hannan et al. (58) examined data from the New York
State Coronary Angioplasty Reporting System Registry
collected between 1998 and 2000, a period when stenting
was used in a large majority of STEMI patients. A non-
signiﬁcant trend towards increased in-hospital mortality
was observed for low-volume operators when compared
with high-volume operators both for volume cutoffs of
8 PPCIs/year (OR: 1.40; 95% CI: 089 to 2.20) and
10 PPCIs/year (OR: 1.27; 95% CI: 0.87 to 1.87). Impor-
tantly, a signiﬁcant increase in the odds of in-hospital
mortality was observed with lower institutional volume
of PPCI, regardless of whether the threshold was set
at 36 PPCIs/year (OR: 2.01; 95% CI: 1.27 to 3.17),
40 PPCIs/year (OR: 1.73; 95% CI: 1.1 to 2.71), or
60 PPCIs/year (OR: 1.45; 95% CI: 1.01 to 2.09). Recently,
Srinivas et al. (99) examined the impact of annual hospital
and physician volume and their interaction on risk-adjusted
mortality in 7,321 patients undergoing PPCI for acute
MI from the New York State PCI Registry (2000 to 2002).
High-volume operators performing >10 PPCIs/year and
those performing>20 PPCIs/year demonstrated a 34% and
37% reduction in risk-adjusted mortality, respectively,
compared with their low-volume counterparts (p < 0.05).
High-volume hospitals (>50 PPCIs/year) also achieved
statistically signiﬁcant reductions in mortality (adjusted
OR: 0.58; 95% CI: 0.38 to 0.88). The thresholds at which
the beneﬁt was observed were similar to the ACCF/AHA
volume recommendations, and as such, the investigators
recommended adherence to current guidelines and the
monitoring of PPCI performance by low-volume operators
(99). A recent analysis (91) explored the relationship
between hospital volume (primary and total PCI volumes)
and patient outcomes in the AHA’s Get With the
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National Registry (2001 to 2007). Hospitals were divided
into tertiles of PPCI volume as low (<36 PPCIs/year),
medium (36 to 70 PPCIs/year), and high (>70 PPCIs/
year). Total PCI volume was similarly calculated, and
hospitals were again divided into tertiles based on the
ACCF/AHA recommended thresholds as low (<200
PCIs/year), medium (200 to 400 PCIs/year), and high
(>400 PCIs/year). A total of 29,513 patients with STEMI
were treated with PPCI at 166 hospitals across the
United States. Hospital annual PPCI volume ranged
between 9 and 225 patients, with a median of 49 (IQR: 27
to 78) patients. Compared with low- and medium-volume
centers, high-volume centers had better median DTB
times (98 versus 90 versus 88 minutes, respectively; p for
trend <0.001) and were more likely to follow evidence-
based guidelines at discharge. The investigators found no
signiﬁcant differences in crude mortality between the PPCI
volume groups, even after sequential multivariable adjust-
ment (91). By contrast, patients presenting to low total PCI
volume hospitals had a higher crude mortality compared
with medium- and high-volume hospitals (3.5% versus
3.3% versus 3.0%, respectively; p for trend ¼ 0.05), which
did not remain statistically signiﬁcant after multivariable
adjustment (91). The importance of the GWTG–CAD
study (91) stems from its inclusion of a large patient pop-
ulation and representation of real-world contemporary
practices from all U.S. census regions. The lack of mortality
beneﬁt, although it stands out in contrast to other reports
(58,92–100), does not eliminate volume as an important
marker of PPCI quality, especially given the differences in
secondary outcomes and quality measures (91).
Although a large body of evidence supports the existence
of a relationship between hospital volume of PPCI and
outcome (Online Appendix 3), only a paucity of studies
related total hospital PCI volume to outcome of acute
MI (79,102). Spaulding et al. (102) examined the rela-
tionship between hospital PCI volume and outcomes after
emergency PCI procedures from the CARDIO-ARHIF
(Agence Régionale d’Hospitalisation d’Ile de France)
Registry, which included a total of 37,848 total PCIs from
44 centers in the greater Paris area (2001 to 2002).
Emergency PCI was deﬁned as PCI performed for acute
MI, cardiogenic shock, or successfully resuscitated out-of-
hospital cardiac arrest. The investigators used a threshold
of 400 PCIs/year to deﬁne low- (<400) and high-volume
(400) centers. In this relatively contemporary study in the
stent era, the investigators found no relationship between
hospital PCI volume and in-hospital mortality for non-
emergency procedures. However, a clear inverse relation-
ship existed between hospital volume and mortality for
emergency PCIs (8.5% versus 6.8%, p ¼ 0.028), which
persisted after multivariable adjustment (102). Com-
plication rates were higher in low-volume centers in
patients undergoing both planned and emergency proce-
dures, even after multivariable adjustment (102). In anothercontemporary study by Zahn et al. (79), a small but
signiﬁcant inverse volume–outcome relationship existed
for in-hospital mortality (using total PCI volume threshold
of 325 PCIs/year); however, this relationship was only
apparent in high-risk subgroups, such as patients presenting
with acute MI. Both of these studies have important
implications (79,102), because they reinforce the notion that
the volume–outcome relationship, if existent in the con-
temporary era, is likely to be most apparent among high-risk
patients undergoing emergency and PPCI procedures.
Based on the available literature, strong evidence exists
for an inverse relationship between hospital PPCI volume,
in-hospital mortality (with the exception of the GWTG–
CAD study) (91) and other major adverse cardiovascular
outcomes. No clear signal relating operator PPCI volume
and hospital total PCI volume to acute MI outcomes
exists. The writing committee endorses the 2011 ACCF/
AHA/SCAI PCI guideline recommendation that PPCI
for STEMI be performed by experienced operators who
perform more than 11 PPCI procedures per year, and
ideally, these procedures should be performed at facilities
that perform >36 PPCI procedures annually (2). However,
the writing committee acknowledges that geographic
challenges to timely access for PPCI may exist in some
areas. Low-volume centers that only perform PPCI (typi-
cally without onsite surgery) and exist to meet critical
access needs must demonstrate acceptable outcomes. This
can be accomplished through the reliance on stringent
systems and process protocols along with close monitoring
of clinical outcomes. Such centers enhance their chance
of success by an association with larger facilities and the
rotation of interventionalists, clinical catheterization lab
staff, and hospital support staff at a high-volume PCI
center (53).
2.8.1.4. OUTCOMES RELATIONSHIP FOR PCI IN HOSPITALS WITHOUT ONSITE
CARDIAC SURGERY
Controversy over the performance of PCI without onsite
cardiac surgery has existed for a considerable time in the
United States, although it is more widely accepted in many
countries abroad (54,103). After publication of the quan-
titative review by Keeley et al. in 2003, the superiority of
PCI over thrombolytic therapy for the treatment of
STEMI became widely accepted (104). This acknowl-
edgement encouraged the development of primary PCI
programs at hospitals without cardiac surgery in an effort
to provide this treatment rapidly to patients with STEMI
in their local communities (105). Difﬁculties sustaining the
proﬁciency of support personnel and operators within
a PCI program limited to patients with STEMI were used
to support the performance of PCI cases in patients pre-
senting without ST-elevation MI at facilities without
onsite cardiac surgery in an attempt to maintain higher
PCI volumes and staff expertise (106,107). Despite
guideline recommendations in place at the time, the
number of PCI facilities without onsite cardiac surgery in
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SCAI published an expert consensus document, which
reviewed the topic of PCI without onsite surgery and
provided recommendations to assure appropriate patient
care in this setting (54). This document acknowledged
the reality that as of 2007, primary and elective PCI without
onsite surgery was already being performed in 28 states
despite the guideline recommendations current at the time.
2.8.1.4.1. THE SAFETY OF PCI WITHOUT
ONSITE CARDIAC SURGERY
As techniques for performing PCI and drug therapies used
during PCI continued to improve, the safety of PCI
without onsite cardiac surgery has been reevaluated in
several recent studies and meta-analyses (33,109–113)
(Online Appendix 4). Separate analyses of registry data
from Sweden and the United States showed no differences
for in-hospital mortality, 30-day mortality, or the need for
emergency CABG surgery among hospitals with and
without onsite surgery (33,109). Two recent meta-analyses
also showed no difference in mortality for primary or non-
primary PCI among hospitals with and without onsite
surgery and no difference in the need for emergency CABG
surgery (110,111). However, in both analyses, heteroge-
neity was observed in the outcomes for non-primary
PCI among sites without onsite surgery, prompting the
authors to make strong recommendations about how such
sites should function to ensure optimal results. Finally, the
Cardiovascular Patient Outcomes Research Team
(CPORT) Non-Primary PCI (CPORT-E) trial random-
ized patients undergoing elective PCI to treatment at
hospitals with and without onsite surgery (113). Within the
context of this well-controlled study, elective PCI at
hospitals without onsite surgery was shown to be not inferior
to PCI at hospitals with onsite surgery.
Reﬂecting the continued accumulation of data on the
safety of PCIwithout onsite surgical backup, themost recent
ACCF/AHA/SCAI PCI guideline classiﬁed primary PCI
without onsite surgery as Class IIa (Level of Evidence: B)
and elective PCI as Class IIb (Level of Evidence: B) indi-
cations, providing appropriate planning for program devel-
opment has been accomplished (2). Elective PCI without
onsite cardiac surgical backup was considered appropriate
only when performed by experienced operators with
complication rates and outcomes equivalent or superior to
national benchmarks. Accurate assessment of complication
rates and patient outcomes via a regional or national data
registry, so that outcomes can be compared with established
benchmarks, is an important quality control component of
any PCI program. Numerous personnel, facility, operator,
and structural requirements adapted from the SCAI expert
consensus documents were described (2,54).
2.8.1.4.2. EXISTING RECOMMENDATIONS FOR
OPERATOR COMPETENCY AT HOSPITALS WITHOUT
ONSITE CARDIAC SURGERY
Noting that PCI without onsite surgery is more routinely
practiced, it is important to emphasize that almost all safetydata come from well-controlled studies or registries at
facilities with a strong commitment to quality outcomes.
Little has been written concerning operator competency
requirements speciﬁcally at hospitals without onsite
surgery, but it is reasonable to assume that outcomes
similar to those reported in the literature would require
facilities and operators to adhere to the same requirements
outlined in the published studies of PCI without onsite
surgery. For example, in CPORT-E, operators were
required to meet the requirements for competency set forth
in the ACCF/AHA/SCAI guideline existing at the time
of the study (minimum 75 PCIs annually), and facilities
were required to have an annual PCI volume of 200 cases
after the ﬁrst year of operation. Within these studies, other
factors noted as contributing to the favorable outcomes in
hospitals without onsite surgery included: a) submitting
data to a national repository for benchmarking; b) linkage
of such facilities to a tertiary care center for consultation; c)
cross-training of personnel; d) similar processes and
structures of care for a patient undergoing PCI; e) expe-
ditious transfer for emergency CABG surgery; and f) use of
risk-adjustment tools for case selection, outcomes analyses,
and comparison of operator performance (33,112,113). It
has also been shown that patients admitted to PCI centers
without onsite surgery have a higher mortality and are less
likely to receive guideline-recommended medications or to
receive reperfusion therapy (114). However, when the
analysis was restricted to patients who received PPCI, the
mortality difference was not signiﬁcant.
The 2011 ACCF/AHA/SCAI PCI guideline empha-
sizes that all PCI programs need a robust quality improve-
ment program that routinely reviews quality and outcomes
for the entire program and for individual operators.
Elements of this Class I recommendation include peer
review of complicated cases or cases with poor outcome
plus random case reviews and participation in a registry so
appropriate benchmarks are established and risk adjust-
ment can be performed. Board certiﬁcation and MOC
in interventional cardiology is strongly encouraged (2).
Maintenance of certiﬁcation in interventional cardiology
currently requires physicians to document a minimum of
150 interventional cases over the 2 years before expiration
of the current certiﬁcation, completion of self-assessment
modules of their medical knowledge, participation in a
practice-based quality-improvement activity, and passage of
a knowledge-based examination. Operator and hospital
volume requirements in the 2011 ACCF/AHA/SCAI
PCI guideline were carried forward from the 2005 guide-
line with the writing committee acknowledging that the
volume recommendations were controversial and should
have a Level of Evidence C rather than B as in the prior
guideline.
The SCAI Expert Consensus Document proposed more
rigorous requirements for operators and facilities without
onsite surgery to reﬂect the opinion of the SCAI writing
group that a greater experience level is appropriate for PCI
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372in the absence of onsite surgery (54). They recommended
that initial operators at a facility without onsite surgery
should not begin performing PCI in such facilities until
they have a lifetime experience of >500 PCIs as primary
operator after completing fellowship. Interventional
cardiologists joining those already engaged in PCI without
onsite surgery with <500 cases of lifetime experience
should be mentored and monitored by qualiﬁed physicians
until it is determined their skills and judgment are satis-
factory and outcomes equivalent or superior to the national
benchmarks. Accordingly, this writing committee recom-
mends operators performing PCI without onsite surgery
should perform >50 total PCIs per year, including >11
primary PCIs per year. Operators who cannot maintain
these case volume recommendations at their primary
practice site should maintain privileges and continue to
perform PCI procedures at a high-volume institution with
onsite surgical backup to meet these annual volume
requirements.y
2.8.1.4.3. VOLUME–OUTCOME RELATIONSHIP AT
FACILITIES WITHOUT ONSITE SURGERY
As noted in an earlier section, the relationship between
both operator and hospital volume and outcomes at facil-
ities with onsite cardiac surgery is not straightforward and
may be inconsistent across low-volume institutions or
operators. This is especially problematic because data
from the NCDR shows a predominance of low-volume
hospitals are facilities without onsite surgery (33,83).
Several strategies have been suggested to ensure optimal
quality and outcomes at low-volume facilities without
onsite surgery, including: a) having both operators and
support personnel rotate at a high-volume facility to
enhance experience; and b) rigorous quality monitoring
program with oversight from a high-volume facility or
formal evaluation by an external accreditation organization.
Performing adequate peer review may be especially difﬁcult
at low-volume facilities with only a few operators. It should
be emphasized, however, that the strongest rationale for
the development of PCI facilities without onsite surgery
was the desire to provide rapid PPCI to patients in their
communities. Since 2000, there has been a substantial
decline in the incidence of STEMI, and there is now
greater emphasis on developing systems of care for STEMI
patients as promoted in the Mission Lifeline initiative
(115,116). All of these factors will further challenge smaller
facilities wishing to sustain PCI programs, potentially
reducing the number of PCIs performed per facility and per
operator. Accordingly, the writing committee recommendsyAlthough the 2011 ACCF/AHA/SCAI PCI guideline includes recommendations
regarding operator and institutional volume, it was anticipated that this current
writing group, tasked speciﬁcally with examining volume thresholds, would be the
primary source and that the 2011 PCI guidelines might be subsequently modiﬁed.
Therefore, the operator and institutional volume discussion, conclusions, and
recommendations in this document supersede the recommendations in the 2011
ACCF/AHA/SCAI Guideline on Percutaneous Coronary Intervention (2).that an institution without onsite surgery with a volume
fewer than 200 procedures annually, unless in a region
underserved because of geography, should strongly consider
whether or not it should continue to offer this service. This
becomes increasingly relevant in an era of declining proce-
dural volumes and expanded institutional capabilities (83).y
2.8.1.5. THE INTERPLAY BETWEEN OPERATOR AND
INSTITUTIONAL PCI VOLUME AND OUTCOME
It has been widely acknowledged that institutional expe-
rience may modify the volume–outcome relationship at the
individual operator level. In 1990, Ryan et al. (65, p. 1473)
recognized that “operator skill and judgment are greatly
inﬂuenced by personal experience . and by the environ-
ment in which the operator practices.”
Hannan et al. (58) demonstrated that, compared with
patients undergoing PCI by high-volume operators (75/
year) in high-volume hospitals (400/year), patients
undergoing PCI by low-volume operators (<75/year) in
low-volume hospitals (<400/year) had signiﬁcantly higher
rates of in-hospital mortality (OR: 5.92; 95% CI: 3.25
to 10.97), same-day CABG (OR: 4.02; 95% CI: 1.04 to
15.57), and same-stay CABG (OR: 3.19; 95% CI: 1.51 to
6.77). A comparison of the size of the effect estimates
showed that the increase in adverse outcomes became
additive when PCIs are performed by low-volume operators
in low-volume hospitals (58). A similar institutional–
operator volume relationship (117) to outcomes was re-
ported in 452,404 patients undergoing PCI in Florida
and New York between 1996 and 2001. Operators
performing 75 PCIs at hospitals performing >400
PCIs had the lowest occurrence of the overall composite
outcome (in-hospital mortality and emergency CABG
surgery) in each year (117). Srinivas et al. (99) demonstrated
a signiﬁcant interaction between hospital and physician
volume with respect to adjusted mortality (p¼0.02) among
acute MI patients undergoing PPCI from the New York
State PCI Registry (2000 to 2002). PPCI by high-volume
physicians (>10 PPCIs/year) in high-volume hospitals
(>50 PPCIs/year) was associated with the lowest risk-
adjusted mortality, followed by high-volume physicians in
low-volume hospitals, low-volume physicians in high-
volume hospitals, and ﬁnally, low-volume physicians in
low-volume hospitals.
2.8.1.6. LIMITATIONS OF THE EXISTING EVIDENCE
The majority of evidence related to volume–outcome rela-
tionship is derived from retrospective administrative data,
observational studies, or large registry data; all of which
have shortcomings (Online Appendices 1–3). Many of
these studies used administrative data to analyze volume–
outcome relations. Incomplete reporting of comorbidities
is an important limitation of administrative data (73,76).
A comparison of administrative versus clinical data in
patients found that the former failed to identify more than
half of patients with a prognostically important condition
Table 4. Possible Predictors of Clinical Outcomes
Following PCI
Case selection
Patient-speciﬁc risk factors
Institutional volume: sharing of techniques, more experience in high-risk cases
Operator volume: annual, lifetime
Appropriateness criteria and indication level
High-risk case selection may be related to higher case volume
Location of hospital: rural/suburban, community, academic teaching
Board certiﬁcation: cognitive learning, evidence-based practice
Reprinted with permission from Klein et al. (128).
PCI indicates percutaneous coronary intervention.
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Administrative data may also be confounded by miscoding,
including increased coding of comorbidities to raise reim-
bursement (118). Additional recognized limitations of
speciﬁc databases exist. When using the Medicare data,
for example, one needs to extrapolate the total number
of procedures from the number of Medicare procedures
(68,70,71,84). By contrast, the GWTG initiative is a
quality improvement registry and not meant to examine
the volume–outcome relationships (91). Data are sub-
mitted voluntarily to the GWTG–CAD database by
participating hospitals and collected by medical chart
review, and are thus dependent on the accuracy and
completeness of abstraction (91). The New York Registry
(58,97,99,101,117) is characterized by mandatory partici-
pation and a comprehensive auditing process, which ensures
accuracy and minimizes self-reporting bias. However,
because of New York’s certiﬁcate of need system, the
number of low-volume hospitals in the registry is limited, so
it is more difﬁcult to study their performance. Data on
timeliness of reperfusion are also lacking, and the general-
izability of data from a single state registry remains ques-
tionable. The latter is not an issue for the Nationwide
Inpatient Sample database, which represents a 20% strati-
ﬁed sample of community hospitals in the United States.
However, the Nationwide Inpatient Sample database does
not capture long-term mortality and clinical outcomes, and
has no information on the severity of the primary diagnosis
or comorbid conditions, which precludes robust risk-
adjustment analyses (78).
Overall, data from these studies should be viewed in the
context of their retrospective observational nature. They
identify only associations rather than causality. In addition,
despite the use of intricate multivariable analyses in the
various studies, no amount of adjustment in regression
models can completely separate the greater illness severity
from worse outcomes, and some portion of the relationship
may still be due to selection bias. Referral bias is also an
important confounder, with low-volume hospitals having
disproportionately more patients with acute coronary
syndrome and a lower percentage of stable coronary artery
disease patients. The National Surgical Quality Improve-
ment Program studies underscored the limitations of
claims data and administrative databases in the provision of
adequate risk-adjustment models that are crucial for
volume–outcome studies (67).
2.8.2. Volume as a Surrogate for Quality
2.8.2.1. PLAUSIBLE EXPLANATIONS FOR THE
VOLUME–OUTCOME RELATIONSHIP
Various factors can explain the relationship between PCI
volume and outcome. It is possible that PCI volume is
correlated with enhanced care processes, including the
implementation of speciﬁc clinical practice guidelines for
patients undergoing PCI or familiarity with treating its
complications and emergencies. The inﬂuence of thelearning effect among operators (high-volume operators
developingmore experience) is also important.High-volume
hospitals are likely to have high-volume operators and,
consequently, experience better outcomes. High-volume
hospitals may also be accepting higher-risk patients with
more complex anatomy that may adversely affect outcomes.
2.8.2.2. LIFETIME PCI EXPERIENCE RELATIONSHIP TO QUALITY
Historically, volume has been used as a surrogate for
quality because it was most easily measureable. However,
we feel it is important to note that volume is only 1 of
many factors affecting the outcome and quality of PCI.
Many studies have emphasized that the quality of systems
of care are more important than volume in determining the
overall quality of procedural care at an institution. Volume
should not be substituted for prospectively monitored and
properly risk-adjusted outcomes (67); however, evaluating
competency is only feasible when an operator or an insti-
tution performs an adequate number of cases to assess risk-
adjusted outcomes. The 2011 ACCF/AHA/SCAI PCI
guideline emphasized that risk-adjusted outcomes remain
preferable to institutional and individual operator volumes
as quality measures (2), outlining the importance to shift
the paradigm from examining volume (a surrogate of
outcome) to direct outcome assessment. Lifetime operator
experience and appropriateness of procedure are also
important metrics. One small study from Japan (7 operators
performing PCI on 121 STEMI patients) demonstrated
that junior cardiologists who performed >50 elective
PCIs can perform PPCI with similar outcomes to experi-
enced operators (>5 years of experience and board
certiﬁed). However, the impact of lifetime operator experi-
ence needs to be explored in larger studies, especially in our
current environment when many experienced operators are
increasingly performing structural interventions at the
expense of lower coronary interventional volume, and older
experienced operators often are required to take less on-call
time than younger members of their group. Periodic case
review to ascertain appropriateness and quality of PCI
procedures is also important (refer to section 2.10.5.1).
Low-risk PCIs performed for the wrong indication are likely
to have favorable outcomes but still reﬂect poor PCI quality
because of inappropriateness of selection. Variables affecting
PCI outcome are summarized in Table 4 (119).
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SPECIFIC VOLUME RECOMMENDATIONS
The 2011 ACCF/AHA/SCAI PCI guideline recom-
mended that PCI should be performed by operators with
an acceptable annual volume (>75 procedures) at high-
volume centers (>400 procedures) with onsite cardiac
surgery (2). These volume recommendations were carried
over from the 2005 ACCF/AHA/SCAI PCI guideline
(25) but downgraded to a Level of Evidence C, recog-
nizing that they represent expert opinion and lack strong
and consistent evidence from the literature. The 2011 PCI
guidelines also encouraged the ACCF/AHA/SCAI Clin-
ical Competence Statement on Cardiac Interventional
Procedures writing committee to review this issue (2).
It is the opinion of our writing committee that the
public, policymakers, and payers should not overemphasize
speciﬁc volume recommendations recognizing that this is
just 1 of many factors that may be related to clinical
outcomes. Notably, 1 report found that <1/3 of physicians
performed >10 PPCIs/year (99), whereas another showed
that >1/3 of U.S. hospitals did not achieve the 36 PPCIs/
year threshold (91). The Leapfrog Group initially focused
on minimum volume standards to measure quality and
encouraged their members to contract with hospitals that
meet minimum volume thresholds (120). However, in
2003, they expanded their measures to include docu-
mented adherence to certain clinical care processes and
direct outcomes measurement (i.e., risk-adjusted mortality)
(121). Of note, the 2010 European Society of Cardiology
Guidelines on Myocardial Revascularization avoided
giving speciﬁc recommendations on operator or hospital
minimum volumes (122).
The relative beneﬁt of more favorable outcomes at facil-
ities with higher volumes must be weighed against the
potential decline in access resulting from minimum volume
standards or regionalization of care. Although regionaliza-
tion of care may ensure better outcomes (especially in the
early stages of a medical intervention), it may also limit
healthcare access and may therefore have negative conse-
quences for patients in less populated areas requiring emer-
gency PCI. After reviewing the preponderance of evidence,
the writing committee could not identify deﬁnite cutoffs for
procedural volume above or below which operators perform
well or poorly. We recognize that advancements in tech-
nology and periprocedural care may result in progressive
improvement in PCI outcomes and may at least partially
offset the adverse institution volume–outcome relationship.
A study evaluating temporal trends in the volume–outcome
relationship in California found that over time, the disparity
in outcomes between low- and high-volume hospitals
had narrowed (73). These ﬁndings were, however, disputed
by others who found no evidence of attenuation over time
of the volume–outcome relationship (82).
Our writing committee recognizes that there are insti-
tutions with low volumes that appear to achieve very
acceptable results just as there are low-volume operatorswith better than expected outcomes and a few high-volume
operators with worse outcomes (85). Because of the like-
lihood of statistical imprecision when examining outcomes
of low-volume operators, other metrics are needed in
addition to volume and risk-adjusted outcomes. It is also
important to account for operators’ lifetime experiences:
many experienced operators are currently performing low-
volume coronary interventional work and shifting to
structural work or a larger portion of administrative duties,
and these should be distinguished from “inexperienced” low-
volume operators. Institutions are encouraged to perform
periodic peer review of random interventional cases for
all operators. Importantly, low-volume operators should
undergo more scrutinized case review. Participation in
regional and national registries such as the NCDR
CathPCI Registry is strongly recommended. Such regis-
tries should provide timely data that are risk-adjusted,
robust, audited, and benchmarked so that clinicians,
hospitals, regulatory bodies and other stakeholders can
accurately assess the quality of care delivered. Additional
emphasis on educational symposia, CME credits, and
simulation courses may provide other venues to enhance
quality for all operators. Currently, several simulation
companies have products designed to present coronary,
peripheral, carotid, and structural cardiac cases that can be
used for teaching or evaluation of cognitive and procedural
skills. The use of these simulators has mostly been in the
area of fellow education or MOC modules, or industry has
used them to train practitioners to use new or less
frequently used devices. Supported by accumulating
evidence, many educators advocate the use of simulator-
based training as a means to complement conventional
training in interventional cardiology (123–126). There are
emerging data suggesting that simulators might serve to
identify low-ability operators; however, the writing
committee acknowledges current technological and access
limitations currently exist, presenting challenges to the
widespread use of simulation (127).
2.8.3. Conclusions
In the current era, volume–outcome relationships are not
as robust as those that were shown when balloon angio-
plasty was the only treatment modality. More recent data
support a modest volume–outcome relationship for vari-
ables other than mortality, but these data have limitations
and are not consistent across all studies. An institutional
volume threshold <200 PCIs/annually appears to be
consistently associated with worse outcomes, but above this
level, there was no relationship between even higher annual
volumes and improved outcomes. Accordingly, the writing
committee recommends a minimum institutional volume
threshold of 200 PCIs per year. There is less evidence to
support a threshold for individual operator volume for both
elective and primary PCI. It is the writing committee’s
recommendation that interventional cardiologists perform
a minimum of 50 PCI procedures per year (averaged over
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committee cautions against focusing on speciﬁc volume
recommendations, and emphasizes that procedural volume
is 1 of several variables to consider when determining
operator competency. Volume is not a surrogate for quality
and should not be substituted for risk-adjusted outcomes
and other measures of quality. Periodic case review and
ascertainment of the appropriateness of procedures should
be performed for all operators and at all institutions. Our
writing committee strongly encourages the participation in
a local or national registry, such as the NCDR CathPCI
Registry, which can help measure performance, assess
appropriateness of procedures, and promote continuous
quality improvement.
2.9. Radial Access
Radial coronary angiography was ﬁrst introduced by
Lucian Campeau in 1989 (129), followed by radial PCI
ﬁrst performed by Ferdinand Kiemeneij in 1992 (130).
Over the last 2 decades, the use of radial coronary angi-
ography and intervention has steadily increased across
Europe, Asia, and Canada (131–133). The penetration of
the radial approach into the United States, however, has
been slow and was estimated at 2% in 2008 (134) but
continues to rise (135). The slow adoption of this tech-
nique in the United States has been due to a prior lack of
formal training during fellowships as well as the lack of
well-deﬁned training pathways for physicians in practice.
Use of the radial artery for diagnostic and interventional
coronary procedures has been compared with the femoral
approach in both observational studies and randomized
trials and has demonstrated signiﬁcant reductions in
bleeding and access site complications (131–134,136,137).
The most compelling evidence supporting the advantages
of radial access comes from the RIVAL (Radial versus
Femoral Access for Coronary Angiography and Interven-
tion in Patients with Acute Coronary Syndromes) trial
(136), which compared outcomes in 7,021 patients
randomized to either radial (n ¼ 3,507) or femoral access
(n ¼ 3,514). Although the primary endpoint (e.g., death,
MI, bleeding, access site complications) was negative, this
trial demonstrated that in certain situations (e.g., patients
presenting with STEMI) a radial approach may be asso-
ciated with signiﬁcant reduction in access site complica-
tions and mortality versus a femoral access approach
(Figure 3). Furthermore, this study supports prior obser-
vations (137,138) reporting a patient preference for the
radial approach noting less discomfort and greater post-
procedural mobility.
The use of a transradial approach, however, is associated
with a steeper learning curve (139), and potential increased
radiation exposure and radial artery occlusion that can be as
high as 30% if best practices are not followed (140). Patient
selection and preprocedural evaluation are critical compo-
nents of assuring a successful transradial procedure. The
ideal patient characteristics include: 1) hemodynamicstability; 2) age <70 years; 3) no history of prior ipsilateral
brachial or transradial procedure; and 4) a palpable radial
artery with a strong pulse and presence of a normal Barbeau
test (141). Relative contraindications to the radial approach
include an absent radial pulse, an abnormal Barbeau test,
severe vasospastic conditions, planned or existing arterio-
venous shunt for dialysis, and the potential use of the radial
artery as a conduit for aortocoronary bypass.
The Barbeau test evaluates the patency of the ulnopalmar
arterial arches by recording both pulse oximetry and
plethysmography during radial artery compression. An
oximetric probe is placed on the ﬁrst ﬁnger or thumb of
the hand where access is to be obtained. When the radial
and ulnar arteries are occluded, the waveform should be
dampened, and no oxygen saturation number can be
recorded. The Barbeau test is more sensitive than the
Allen’s or modiﬁed Allen’s tests, and classiﬁes patients into
4 groups. If the waveform remains dampened after release of
the compressed ulnar artery, the test is considered abnormal
(type D), and the radial artery should not be punctured.
Type D pattern usually occurs in only 1.5% of patients.
2.9.1. Training
Current interventional cardiology training program
guidelines provide no speciﬁc recommendations regarding
training for the transradial approach. The ACCF Core
Cardiology Training Symposium (COCATS) guidelines
state that one needs the ability to “perform vascular access
from the femoral, radial, or brachial route” (142). Also, the
current ACGME Program Requirements for Graduate
Medical Education in Interventional Cardiology states that
“Fellows must have formal instruction, clinical experience,
and must demonstrate competence in the performance of
coronary interventions [via] femoral and brachial/radial
cannulation of normal and abnormally-located coronary
ostia” (3, p. 10).
Ideally, interventional fellows would graduate with
competency in radial and femoral procedures, and prac-
ticing physicians would have a well-deﬁned pathway to
gain these skills. However, this has not come to fruition in
the United States due to the small number of radial
procedures and the limited number of interventional
cardiologists skilled in this technique. Training in radial
coronary angiography and interventions should include
acquisition of knowledge and competence in the following:
1. Anatomy of the upper extremity vasculature
2. Patient evaluation and selection for transradial
approach
3. Selection of right or left transradial approach
4. Patient preparation and room set-up
5. Radial artery access
6. Arterial vasodilators and antithrombotic pharmacology
7. Catheter selection and manipulation for diagnostic
and interventional procedures
8. Troubleshooting during transradial approach
Figure 3. Forest Plot of the Updated Meta-Analysis (RIVAL Trial)
*Deﬁned as centers with radial as the preferred route or known expert centers for pre-RIVAL, and centers with the highest tertile radial intervention center volume for RIVAL.
CABG indicates coronary artery bypass graft surgery; CI, conﬁdence interval; MI, myocardial infarction; OR, odds ratio; and RIVAL, Radial vs. Femoral Access for Coronary
Angiography and Intervention in Patients with Acute Coronary Syndromes trial. Reprinted with permission from Jolly et al. (136).
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complications
10. Sheath removal and access site management
For physicians in practice, the number of cases required
for competency will be based on the expertise of the oper-
ator. The learning curve for any new procedure partially
depends on the cumulative experience of the operator in
catheter-based interventions. Fellows in training will need
prospectively deﬁned curricula that cover the spectrum of
cognitive and technical skills required to master this
approach.
2.9.2. Competency
Currently, there are no standard guidelines that deﬁne
competency in radial angiography and interventions. The
SCAI subcommittee for transradial angiography and
intervention proposed the following criteria (141):
 Level 1 competency: able to perform simple diag-
nostic cases on patients with favorable upper limb
anatomy (large men)
 Level 2 competency: Able to perform simple diag-
nostic and interventional procedures on patients with
more challenging upper limb anatomy (elective single
vessel PCI; bypass grafts, small women, radial and
subclavian loops) Level 3 competency: Able to perform complex
interventional procedures even with challenging
limb anatomy (chronic total occlusions, multivessel,
acute MI)
At the present time, as such pathways develop, the
outcomes of PCI procedures via the radial approach should
be assessed in a similar manner to that of other PCI
procedures, with attention to bleeding, access site com-
plications, and overall outcomes. These procedures should
be included in the overall volume statistics for the operator,
and institutions or operators may wish to separately eval-
uate operator or laboratory performance based upon route
of access. Further expansion of specialized training courses
for interventional cardiologists already in practice wanting
to acquire competencies in radial coronary angiography and
PCI should be provided to meet current needs.2.10. Quality Assurance
2.10.1. Deﬁnition of Quality in PCI
Quality in PCI includes selecting appropriate patients for
the procedure, achieving risk-adjusted outcomes that are
comparable to national benchmark standards (in terms of
procedural success and adverse event rates), using reason-
able resources, achieving quality procedure execution
Table 5. PCI Outcomes and Adverse Events
Major outcomes
Mortality (in-hospital, 30 day)
Unplanned CABG surgery (same day, same stay: urgent vs. elective)
Stroke, TIA, or other neurological events
Myocardial infarction* or ischemia
Arrhythmias requiring treatment
Cardiac arrest in the cardiac catheterization laboratory
Hemodynamic instability requiring therapy
Major contrast reaction
Procedural adverse events
Coronary
Abrupt closure requiring speciﬁc therapy
Distal embolization/no reﬂow
Coronary perforation
Cardiac tamponade
Stent thrombosis
Other AEs (e.g., stent loss, retained foreign body, guidewire fracture)
Systemic/Peripheral
Contrast-induced nephropathy/new requirement for dialysis
Excess radiation dose (ﬂuoroscopy time/dose)
Intracranial hemorrhage
Vascular site complications
Major drop in hemoglobin (>3.0 g/L) or requirement for blood
transfusion
Major bleeding
Access site vascular injury
Retroperitoneal hemorrhage
Arterial access vessel occlusion or dissection
Access site infection
DVT/pulmonary embolism
Other AEs (e.g., stent lossdperipheral)
Additional measures
Door-to-balloon time in STEMI
Wrong patient or procedure
*Universal Deﬁnition of Myocardial Infarction should be employed. Adapted with permission
from Klein et al. (128).
AEs indicates adverse events; CABG, coronary artery bypass graft surgery; DVT, deep vein
thrombosis; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction;
and TIA, transient ischemic attack.
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and providing an acceptable patient experience (143). To
achieve optimal quality and outcomes in PCI, including
acceptable angiographic, procedural, and clinical success
rates, it is necessary that operators and the supporting
institution be appropriately skilled and experienced, collect
data to allow quality analysis, and have established
appropriate systems of care.
2.10.2. Institutional Requirement for a
Quality Assurance Program
In the United States, responsibility for quality assurance
is vested in the healthcare institution that is responsible
to the public to ensure that patient care conducted under
its jurisdiction is of acceptable quality. Quality assurance
should include continuous quality assessment and im-
provement (QI) processes, and should be conducted at
the levels of the entire program and the individual
operator.
The writing committee supports the recommendation of
the 2011 ACCF/AHA/SCAI PCI guideline that every
PCI program should operate a quality improvement
program that routinely: 1) reviews quality and outcomes of
the entire program; 2) reviews results of individual opera-
tors; 3) includes risk adjustment; 4) provides peer review of
difﬁcult or complicated cases; and 5) performs random case
reviews (2). Each institution that provides PCI services
must establish an ongoing mechanism for valid and
continuous peer review of its quality and outcomes. The
program should provide an opportunity for interventional
cardiologists and all involved physicians, including
members of an integrated heart team, to review its overall
results on a regular basis and receive periodic feedback to
enhance deﬁciencies in PCI care. The review process
should tabulate the outcomes achieved both by individual
operators and the overall program, and compare them with
national benchmark standards with appropriate risk
adjustment. The review process should also assess the
appropriateness of the interventional procedures, and
examine other procedural variables pertinent to quality
execution of the procedure, periprocedural management,
and resource utilization. Valid quality assessment requires
that the institution maintain meticulous and conﬁdential
records that include patients’ demographics and clinical
characteristics necessary to assess these measures and
conduct risk adjustment in a transparent manner.
An independent and dedicated committee should be
established and ideally include both physicians and relevant
healthcare personnel in a cooperative effort minimizing any
conﬂict of interest. Interventional cardiologists are best
suited to perform the primary role in evaluating PCI
quality and leading the quality assurance program. The
process should be instituted with the support of hospital
administrators who can help provide resources for registry
participation, conduct analyses, and support other aspects
of the QI process. The hospital risk managementdepartment, responsible for investigating reported events
and government-mandated quality indicators, should work
in cooperation with the physician-led quality assurance
program. Use of the data for non-QI purposes (e.g.,
marketing strategies, improving referral) should be strongly
discouraged. Programmatic deﬁciencies, in particular,
should be identiﬁed with the involvement of hospital risk
management, when appropriate.
The institution should also ensure that all operators
are properly trained and certiﬁed (including MOC) and
possess the cognitive knowledge and technical skills re-
quired to perform PCI (144).
2.10.3. Complexity of Determination of PCI Quality
2.10.3.1. IDENTIFICATION OF PCI QUALITY INDICATORS
Components of an optimal quality assurance program
require that several outcome and process measures are
routinely and timely collected and analyzed. A dedicated
database must be established with hospital support and
should include explicitly deﬁned quality indicators that
reﬂect patient outcomes and processes of care. Table 5
provides an example of core PCI outcomes and measures
that every quality assurance program is encouraged to
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QI process can be best implemented by incorporating
clinical practice guidelines and appropriateness criteria for
coronary revascularization (2,52), as they have been shown
to improve clinical outcomes (59,145,146).
2.10.3.2. ROLE OF RISK ADJUSTMENT IN ASSESSING QUALITY
An adverse event rate that is not appropriately risk-
adjusted has limited value. Data compiled from large
registries of PCI procedures have generated multivariable
risk adjustment models for mortality and other adverse
events. Most of these models are based on logistic
regression analyses of in-hospital events (predominantly
mortality) using a large number of prospectively-collected
variables. Notably, many of these models were derived
from earlier patients’ cohorts, and are outdated in the
current era of rapidly evolving technology and medical
therapy. Contemporary PCI risk scores and predictive
models are summarized in Online Appendix 5 (31,
147–153). Sufﬁcient resources must be available to ade-
quately measure baseline patient risk permitting valid risk
adjustment of outcomes and determining appropriateness
of the intervention.
2.10.3.3. NATIONAL BENCHMARKING
National benchmarking is a means to compare a physi-
cian’s clinical practice and patient outcomes against his/her
peers, and is a valuable means to understand high variances
in low incidence adverse events (154). Benchmarking
requires standardized collection of clinical and procedural
data for PCI using identical elements that are entered
into a single electronic repository. This allows regular
comparison of risk-adjusted outcomes and complications
with national standards. A complete and accurate com-
prehension of clinical results requires benchmarking of
risk-adjusted outcomes to account for differences in patient
characteristics and avoid self-reporting bias (155). Ap-
propriate short-term follow-up should also be arranged
prior to discharge, because 30-day outcomes have become
increasingly required for reimbursement purposes.
The writing committee of the current Clinical Com-
petence Statement echoes the 2011 ACCF/AHA/SCAI
PCI guideline in encouraging the participation in a recog-
nized national quality database. Registries such as the
ACCF NCDR CathPCI Registry (156,157), which
began in 1998, are designed to standardize reporting of
catheterization laboratory outcomes. These types of clinical
registries offer the opportunity to have a comprehensive
national reporting system that fulﬁlls the goals of assessing
and benchmarking quality and outcomes. They can also be
utilized to measure performance and utilization rates,
promote continuous quality improvement, conduct post-
market drug and device surveillance, assess appropriate-
ness of procedures, and track patient safety (154). We look
forward to the expansion of currently available databases to
better capture important safety, longer-term outcome,
quality of life, and resource utilization measurements.2.10.3.4. OTHER CHALLENGES IN DETERMINING QUALITY
Given the complexity of case selection and procedure
conduct, quality is difﬁcult to measure in PCI and is not
determined solely by adverse event rates even when prop-
erly risk-adjusted. Notably, procedural volume is a weak
and inconsistent measure of quality, and it should not be
used alone as a quality indicator. In addition, only short-
term outcomes (such as in-hospital mortality) are usually
used as the benchmark for risk-adjusted outcomes, and
long-term outcomes (including repeat revascularization,
recurrent MI, death, and re-hospitalization rates) are often
underutilized. Accurate assessment of quality is more
problematic for low-volume operators and institutions
because of small expected absolute event rates and issues of
statistical imprecision. Thus, particularly in low-volume
circumstances, quality may be better assessed by an
intensive case-review process. Case review also has merits
in very high-volume situations as it can identify subtleties
of case selection and procedure conduct that may not be
reﬂected in pooled statistical data. It is the opinion of the
writing committee that all operators should undergo
periodic peer review, with more intensive review process
for low-volume operators. Although performance of very
high-volume operators is more easily monitored using risk-
adjusted outcomes models with comparison to national
benchmarks, these operators should also be reviewed for
the appropriateness of procedures and indications criteria
to assure the clinical necessity of these procedures. Finally,
the possibility of conﬂicts of interest among competing
physicians exists. It is therefore strongly advised that a formal
method of oversight for perceived conﬂicts of interest among
peer reviewers be used and carefully scrutinized.
2.10.4. Requirement for Institutional Resources
and Support
A high-quality PCI program requires appropriately
trained, experienced, and skilled operators. However, the
operator does not work in a vacuum, but rather needs
a well-maintained high-quality cardiac catheterization
facility to practice effectively. In addition, the operator
depends on a multidisciplinary institutional infrastructure
for support and response to emergencies, including
adequate cardiothoracic surgical support (onsite or with
a pre-deﬁned strategy for offsite surgical back-up). System
“stress test” drills to assess logistics ﬂow capabilities of both
the referring and receiving centers can help reﬁne a well-
coordinated emergent transfer. Therefore, to provide
quality PCI services, the institution must ensure that its
catheterization facility is properly equipped and managed,
and that all of its necessary support services, including data
collection, are of high quality and are readily available.
Educational activities such as cardiac catheterization and
quality improvement conferences should be encouraged by
the institution and should be held routinely. Presentation
of clinical and technically challenging cases, including
those with complications and unexpected developments
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reviews, is important. Advances in current communication
technologies, such as video conferencing or simulcast case
reviews, can facilitate this process. It is important to
appreciate that the separation of peer review from more
traditional teaching activities is most appropriate for
optimal quality assurance.
2.10.5. Quality Assessment and
Implementation Processes
Quality assessment is a complex process that includes more
than a mere tabulation of success and complication rates.
The PCI quality assurance program should be compre-
hensive and evaluate multiple patient subsets so as to
promote both individual physician and system-wide quality
improvement.
The core of most PCI quality assurance programs
should include: a) the collection of clinically relevant data,
which contain variables that allow assessment of clinical
processes, performance, and outcomes; b) feedback of this
performance and outcomes data to clinicians, ideally with
risk-adjustment and benchmarking of the data; and c)
implementation of appropriate interventions to promote
reduction in inefﬁcient variation in care while simulta-
neously improving performance (158). PCI quality assur-
ance must include an ongoing, peer review assessment of
the clinical proﬁciency of each operator including random
case review, realistic identiﬁcation of programmatic and
individual operator strengths and weaknesses, and
comparison of individual and aggregate outcomes against
national standards and benchmark databases. Components
of quality in coronary interventional procedures include: a)
appropriateness of case selection; b) quality of procedural
execution; c) proper response to intra-procedural problems;
d) accurate assessment of procedural outcome both short-
and long-term; and e) appropriateness of periprocedural
management. SCAI recently published a report to establish
the standard by which interventional program quality
should be measured (128). Quality includes the ability
of an interventional cardiologist to provide safe and efﬁ-
cient care to appropriately selected patients, and the
expertise to treat a wide range of coronary pathology in
these patients.
2.10.5.1. THE PEER REVIEW PROCESS
The quality assessment process should also conduct
random and detailed reviews of both cases that have
adverse outcomes, to determine the causes of the adverse
events, and of uncomplicated cases, in order to judge case
selection appropriateness and procedural execution quality.
These reviews should be conducted by recognized, expe-
rienced, unbiased interventional cardiologists, drawn either
from within the institution or externally. Noninvasive
cardiologists may also participate in the review committees,
especially when it comes to assessing procedural appro-
priateness. A timely and periodically conducted reviewprocess is essential as the reviewers should provide
continuous feedback to the institutions and operators to
enhance the care process. Review of cineangiography ﬁlms
should be undertaken to address technical issues. External
review represents a second layer of unbiased review of the
interventional program. The Accreditation for Cardiovas-
cular Excellence (ACE), initially created by the SCAI in
2010 and cosponsored by the ACCF, is 1 example of an
external peer review body, which offers formal, objective,
and independent evaluation and monitoring to PCI
facilities to ensure that they meet the highest possible
standards for patient care and safety. Other forms of
external review options exist and individual institutions
will need to determine the appropriate external review
option for its particular clinical needs, should that be
desired. Conﬁdential and constructive feedback of
performance and outcomes data should be given to clini-
cians to promote changes in practice and improve perfor-
mance (158).
2.10.5.2. METHODS OF REMEDIATION
When the continuous quality improvement process iden-
tiﬁes a systemic problem that requires remediation, the
quality assurance committee must investigate the root
cause and devise a solution. A formalized plan and
implementation strategy (including continued reassess-
ment) should be proposed, and ongoing modiﬁcation may
be required to reach the target result. Recommendations
should be based on a comprehensive knowledge of the
issue and input from all appropriate stakeholders. When
concerns with operator performance arise, remediation
should be implemented in a stepwise fashion. Remedia-
tion methods may start with an initial discussion with the
operator, followed by a nonpunitive action plan with
appropriate and constructive feedback, such as proctoring
a number of cases by the lab director or an experienced
operator, as well as additional CME requirements. If this
is unsuccessful or the operator is uncooperative with the
plan of remediation, then the next steps may include
referral to an external agency or internal hospital
committee which may result in penalties or sanctions for
the operator, and possibly revocation of the operator’s
privileges.
2.10.5.3. CONFIDENTIALITY
The Federal Health Care Improvement Act of 1986
recognized the importance of quality assurance programs
and the importance of protecting participants and their
deliberations. Protecting patient safety is most important
in the quality assurance process. The committee must
behave equitably and transparently to ensure fairness to the
operator, quality for the patient, and credibility for the
committee. Outcomes must be presented while maintain-
ing absolute conﬁdentiality of the operators. Use of
conﬁdential information to target an individual physician
should not be allowed.
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The cornerstone of quality assurance monitoring is the
transparent reporting and continued assessment of proce-
dural outcome data including adverse events. Equally
important components include establishing criteria for
assessing procedure appropriateness and applying proper
risk adjustment to interpret adverse event rates. A quality
interventional program performs appropriately selected
procedures while achieving risk-adjusted outcomes that are
favorably comparable to national benchmark standards.
There has been considerable controversy surrounding the
efforts to deﬁne standards and methodologies for con-
ducting quality assurance. An objective, physician-led
process that includes appropriate evaluation and correc-
tive action plans and is organized to assure a fair and
impartial review of performance, provides a reasonable level
of assurance that quality is being accurately assessed and
promoted. An effective process should also include random
case review, develop critical pathways, and accomplish and
document positive changes in practice.
2.11. Summary of Key Recommendations for PCI
Physical Facility and Institutional Requirements
(see Section 2.5.1)
Physical Facility Requirements:
 The facility must provide the necessary radiological,
monitoring, and adjunctive patient support equipment
to enable operators to perform in the safest and most
effective environment.
 The real-time ﬂuoroscopic and acquired image quality
must be optimal to facilitate accurate catheter and device
placement and facilitate the correct assessment of
procedural results.
 Physiological monitoring equipment must provide
continuous, accurate information about the patient’s
condition.
 Access to other diagnostic modalities such as intravas-
cular ultrasound and fractional ﬂow reserve should be
available.
 Hemodynamic support devices such as intra-aortic
balloon pumps and percutaneous ventricular assist
devices should be available in institutions routinely
performing high-risk PCI.
 These requisite support equipment must be available
and in good operating order to respond to emergency
situations.
Institutional Requirements:
 The interventional laboratory must have an extensive
support system of speciﬁcally trained laboratory
personnel. Cardiothoracic surgical, respiratory, and
anesthesia services should be available to respond to
emergency situations in order to minimize detrimental
outcomes. The institution should have systems for credentialing,
governance, data gathering, and quality assessment.
Prospective, unbiased collection of key data elements on
all patients and consistent timely feedback of results to
providers brings important quality control to the entire
interventional program and is critical to assessing and
meeting appropriate use criteria for coronary
revascularization.
 The writing committee endorses the ACCF/AHA/
SCAI PCI guideline (2) recommendations that:
B Primary PCI is reasonable in hospitals without onsite
cardiac surgery, provided that appropriate planning
for program development has been accomplished
(Class IIa).
B Elective PCI might be considered in hospitals without
onsite cardiac surgery, provided that appropriate
planning for program development has been accom-
plished and rigorous clinical and angiographic criteria
are used for proper patient selection (Class IIb).
B Primary or elective PCI should not be performed in
hospitals without onsite cardiac surgery capabilities
without a proven plan for rapid transport to a cardiac
surgery operating room in a nearby hospital or
without hemodynamic support capability for transfer
(Class III).
 System “stress test” drills to assess logistics ﬂow capa-
bilities of both the referring and receiving centers can
help reﬁne a well-coordinated emergent transfer.
Components of Operator Competence (see Section 2.7)
 See Table 3 for the components of operator competence
for PCI utilizing the ACGME core competency
structure pertaining to medical knowledge; patient care
and procedures; practice-based learning; systems-based
practice; interpersonal and communication skills; and
professionalism.
Maintenance of Quality
Institutional (see Section 2.8.1.1)
 Full-service laboratories (both primary and elective
PCI, with and without onsite cardiac surgery)
performing <200 cases annually must have stringent
systems and process protocols with close monitoring of
clinical outcomes and additional strategies that promote
adequate operator and catheterization laboratory staff
experience through collaborative relationships with
larger-volume facilities. The continued operation of
laboratories performing <200 procedures annually that
are not serving isolated or underserved populations
should be questioned, and any laboratory that cannot
maintain satisfactory outcomes should close.
Individual Operator (see Section 2.8.1.2)
 The individual operator level volume is 1 of several
factors that should be considered in assessing operator
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381competence, including lifetime experience, institutional
volume, individual operator’s other cardiovascular
interventions, and quality assessment of the operator’s
ongoing performance.
 Interventional cardiologists should perform a minimum
of 50 coronary interventional procedures per year
(averaged over a 2-year period) to maintain competency.
 Facilities should develop internal review processes to
assess operators <50 PCIs annually.
 Additional emphasis on educational symposiums, CME
credits, and simulation courses may provide other
venues to enhance quality for all operators.
 These recommendations supplant the recommendations
in the 2011 ACCF/AHA/SCAI Guidelines on PCI.
 Operators should have ABIM board certiﬁcation in
interventional cardiology and maintain certiﬁcation,
with the exception of operators who have gone through
equivalent training outside the United States and are
ineligible to take the ABIM certiﬁcation and recertiﬁ-
cation exams.
Primary PCI (see Section 2.8.1.3)
 Primary PCI for STEMI should be performed by
experienced operators who perform a minimum of
50 elective PCI procedures per year and, ideally, at least
11 PCI procedures for STEMI per year. Ideally, these
procedures should be performed in institutions that
perform more than 200 elective PCIs per year and more
than 36 primary PCI procedures for STEMI per year.
 These recommendations supplant the recommen-
dations in the 2011 ACCF/AHA/SCAI Guidelines
on PCI.
Quality Assurance
Institutional Requirements (see Section 2.10.2)
 Each institution that provides PCI services must estab-
lish an ongoing mechanism for valid and continuous
peer review of its quality and outcomes.
 To reach these goals, every PCI program should
operate a quality improvement program that routinely:
1) reviews quality and outcomes of the entire program;
2) reviews results of individual operators; 3) includes
risk adjustment; 4) provides peer review of difﬁcult
or complicated cases; and 5) performs random case
reviews.
 The review process should assess the appropriateness
of the interventional procedures. Evaluation should
include both the clinical criteria for the procedure and
the quality and interpretation of the angiograms.
 Valid quality assessment requires that the institution
maintain meticulous and conﬁdential records that
include patients’ demographics and clinical characteris-
tics necessary to assess these measures and conduct risk
adjustment in a transparent manner. An independent and dedicated committee should be
established and ideally include both physicians and
relevant healthcare personnel in a cooperative effort
minimizing any conﬂicts of interest. Interventional
cardiologists are best suited to perform the primary role
in evaluating PCI quality and leading the quality
assurance program.
 The process should be instituted with the support of
hospital administrators, who can help provide resources
for registry participation, conduct analyses, and support
other aspects of the QI process.
Institutional Resources and Support (see Section 2.10.4)
 The institution must ensure that its catheterization
facility is properly equipped and managed, and that all
of its necessary support services, including data collec-
tion, are of high quality and are readily available.
 Educational activities such as cardiac catheterization and
quality improvement conferences should be encouraged
by the institution and should be held routinely.
Presentation of clinical and technically-challenging
cases, including those with complications and unex-
pected developments during the conduct of a PCI along
with appropriateness reviews, is important.
National Benchmarking (see Sections 2.8.2.3 and 2.10.3.3)
 Participation in regional and national registries such as
the NCDR CathPCI Registry is strongly encouraged.
Such registries should provide timely data that are
risk-adjusted, robust, audited, and benchmarked so that
clinicians, hospitals, regulatory bodies, and other stake-
holders can accurately assess the quality of care delivered.
Quality Assessment and Implementation Process
(see Sections 2.10.3.3, 2.10.3.4, 2.10.5, and 2.10.5.1)
 PCI quality assurance must include an ongoing, peer
review assessment of the clinical proﬁciency of each
operator including random case review, realistic identi-
ﬁcation of programmatic and individual operator
strengths and weaknesses, and comparison of individual
and aggregate outcomes against national standards and
benchmark databases.
 Performance of all operators should be monitored using
risk-adjusted outcome models with comparison to
national benchmarks, and operators should be reviewed
for the appropriateness of procedures and indications
criteria to ensure the clinical necessity of the procedures.
 All operators should undergo periodic peer review, with
more intensive review process for low-volume operators.
 In instances where operators are performing less than
the suggested range, both institutions and operators are
strongly encouraged to carefully assess whether their
performance is adequate to maintain their competence
and whether they should continue performing coronary
interventions.
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382 A formal method of oversight for perceived conﬂicts of
interest among peer reviewers should be used and
carefully scrutinized.
 The quality assessment process should conduct random
and detailed reviews of both cases that have adverse
outcomes, to determine the causes of the adverse events,
and of uncomplicated cases, in order to judge case
selection appropriateness and procedural execution
quality. These reviews should be conducted by recog-
nized, experienced, unbiased interventional cardiologists
drawn either from within the institution or externally.
Noninvasive cardiologists may also participate in the
review committees, especially when it comes to assessing
procedural appropriateness.
 A timely and periodically conducted review process is
essential as the reviewers should provide continuous
feedback to the institutions and operators to enhance
the care process.
 Review of cineangiography ﬁlms should be undertaken
to address technical issues.
 Conﬁdential and constructive feedback of performance
and outcomes data should be given to clinicians to
promote changes in practice and improve performance.
 Addressing limitations of currently available databases
to include other important quality metrics such as longer
term efﬁcacy and safety endpoints, quality of life, and
resource utilization would be helpful in determining
quality performance.3. Other Coronary Interventions
Coronary interventions are occasionally required to provide
an invasive therapeutic approach to hypertrophic cardio-
myopathy, ventricular tachycardia (VT), and coronary
ﬁstulae. These are rare clinical situations that pose a unique
problem for the establishment of operator and staff
competency. These procedures should only be performed
in major centers where there is a particular interest in the
disease processes and adequate clinical volume to provide
experience in the appropriate interventional techniques. A
dedicated multidisciplinary team should be in place. These
procedures require such a multidisciplinary team approach
that involves cardiologists, surgeons, technicians, and
nurses all working together to achieve optimal results.
3.1. Alcohol Septal Ablation for
Hypertrophic Obstructive Cardiomyopathy
3.1.1. Background
The ﬁrst description of the use of alcohol septal ablation
for hypertrophic obstructive cardiomyopathy (HOCM)
appeared in 1995 (159) and the 10-year follow-up of that
ﬁrst group of 12 patients was recently reported (160).
Although most studies have reported single-institutional
data, the multicenter North American Registry data(161) reviewed 874 patients who had undergone the
procedure. A mortality rate of 0.7% from the procedure
was reported. This latter group outlined the major
complications associated with the contemporary use of
the procedure and the clinical variables that predicted
death during follow-up. A recent single-institution non-
randomized report of 177 patients who had alcohol
ablation for HOCM revealed a survival rate similar to
both the general population and to an age- and gender-
matched surgical myomectomy cohort at 5.7 years of
follow-up (162).
The principle of alcohol ablation depends on the local-
ized injection of alcohol into a septal perforator artery
that supplies the basal interventricular septum to create a
controlled MI that will eventually lead to septal scarring
and thinning. Localization requires identifying of the
myocardium subtended by the coronary perforator. To
properly perform the procedure requires a thorough knowl-
edge of the geometric substrate. Usually, left ventricular
outﬂow track (LVOT) obstruction is caused by asym-
metrical septal hypertrophy and anterior displacement of
the papillary muscle resulting in contact of the septum
and anterior mitral leaﬂet during systole. However, LVOT
gradients may also result from an abnormal mitral valve
with redundant leaﬂets or accessory chordae. In addition,
changes in aortoventricular alignment may also create
obstruction with normal or only mild septal hypertrophyda
feature of LVOT obstruction in the elderly. Finally,
gradients at the midventricular level or toward the left
ventricular apex may not have the appropriate septal
perforator supply and would not be appropriate for the use
of alcohol ablation techniques. A thorough knowledge of
catheterization anatomy and coronary interventional tech-
niques, as well as echocardiographic and (even magnetic
resonance imaging) imaging of the left ventricular and
mitral apparatus anatomy, is therefore critical in some cases
of HOCM. These skills are a prerequisite for selection of
the appropriate patients and for the successful performance
of these studies.
The 2011 ACCF/AHA Guideline for the Diagnosis
and Treatment of Hypertrophic Cardiomyopathy (163)
outlines a suggested treatment algorithm for the appro-
priate use of alcohol septal ablation in the treatment of
symptomatic patients with HOCM. It is important that
these procedures be performed only at specialized centers
dedicated to the comprehensive and multidisciplinary
treatment of these patients.
3.1.2. Criteria for Competency
3.1.2.1. OPERATOR COMPETENCY
Using the ACGME core competencies to deﬁne the
issues, it is the recommendation of this writing committee
that the following be considered:
Patient Care: The operator should have a thorough
knowledge of the impact HOCM physiology plays in
the patient’s symptom complex. Many of the symptoms
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383attributed to HOCM overlap with other disease states,
particularly if there is concurrent lung disease, coronary
disease, anemia, etc., so optimal patient care requires the
operator to differentiate symptoms related to HOCM from
these other issues. Medical therapy should be appropriate
and considered to have been a failure before the procedure
is attempted. At least 1 dedicated surgeon with a working
knowledge of myectomy and valve repair should be part of
the overall program, and there should be regular case
reviews. For complex cases, surgical consultation should be
sought, and the multidisciplinary team should agree that
the interventional procedure is warranted. Nursing staff
should be trained to recognize complications, both early
and late, following the procedure.
Medical Knowledge and Procedural Volume: To gain the
appropriate skill set for the performance of alcohol ablation
requires the knowledge base related to the disease process
(as described above) and the technical skills to safely
perform the procedure. Medical knowledge regarding the
procedure can be gained at courses at major meetings,
participation in clinical trials or by working with colleagues
at one’s own institution or at another facility.
To gain the particular skill of alcohol ablation for
HOCM patients, the committee suggests that initially
each operator perform the ﬁrst 5 studies in a proctored
situation assisting a skilled operator. These procedures
could be done at the operator’s own facility or at the skilled
operator’s facility. The ACCF/AHA HOCM guideline
suggests that an experienced operator should not be deﬁned
until one has performed >20 procedures or the procedures
have all been performed at a facility that has a cumulative
volume of 50 procedures. If the procedures are performed at
a facility with a cumulative experience of <50 cases, it is
recommended that the catheterization laboratory quality
assurance committee (or one appointed by the institution)
be responsible for reviewing all of the ﬁrst 20 cases per-
formed. For maintenance of skills, it is recommended
that each individual principal operator perform at least
10 procedures per year. This latter number has also been
suggested in a report from the SCAI training program
directors (164) as being the minimal number for certiﬁ-
cation of cardiovascular trainees within the structural heart
disease program who desire alcohol ablation skills as part of
their interventional training.
The minimal number of procedures, however, does not
correlate with either operator skill or patient outcomes.
The committee feels strongly that alcohol ablation for
HOCM should be performed only with a multidisci-
plinary team, and that volume is just 1 of many factors
that should be considered in assessing operator compe-
tency. After each operator has developed the needed
skillset in a proctored environment, then, given the rarity
of the procedure, 5 alcohol ablations for HOCM per
year should be considered a reasonable volume to maintain
that skillset. The bottom line remains that the onus is on the
local credentialing process and the quality assurancecommittee to ensure an operator is qualiﬁed and his/her
procedural outcomes are of the highest possible quality.
Practice-Based Learning: The facility should provide a
regular forum for the presentation of individual cases and
provide the operators with feedback on the techniques
and results obtained. These reviews should stress the use
of evidence-based therapy and discuss best practices. As
the ﬁeld develops, these regular conferences should stress
ways to improve the procedure and both institutional
and individual outcomes. Literature reviews should be
incorporated and veriﬁcation conﬁrmed that the practices
being used conform to the established guidelines.
Interpersonal and Communication Skill: At the recom-
mended periodic review sessions, any communication or
conﬂicts regarding the appropriateness of the procedures or
the technical issues should be directly discussed. Patient
satisfaction should be addressed and criticisms acted upon.
Feedback from staff and nursing should also be provided to
ensure optimal patient care is being performed and that
staff members are receiving the appropriate training.
Professionalism: Any criticism of the handling of the
patient’s care at any stage should be addressed. This
includes ensuring the patient and his family understand
the procedure, are treated respectfully and honestly, the
consent process is clear, the referring physician is kept well
informed, and all of the team members are acknowledged
for their contributions.
Systems-Based Practice: The facility should have a formal
commitment to the structural heart disease program and
be supportive of establishing and maintaining the highest
quality. Because care of the patient requires careful follow-
up, it is important that the practitioners in the entire health
system be aware of the potential complications from the
procedure, and that a system is in place that allows for
potential issues to be addressed should an untoward event
occur after the procedure. Because many patients will
receive the bulk of their care locally and not at the referral
center, a systems-wide educational effort should be made
to inform the healthcare professionals of the indications
and contraindications of the procedure and the expected
outcomes. A clear mechanism should be in place that
allows ready access to a member of the procedural team
should questions arise.
3.1.2.2. STAFF COMPETENCY
Many of the core competencies that apply to the operator
are transferrable to staff involved as well. There should be
a dedicated staff that has an interest in the procedure. It
is particularly important that the cardiac catheterization
team and the echocardiographic team work together,
and they are considered a vital part of the procedural
effort. The staff should be trained to anticipate all aspects
of the procedure. Not only should initial training be
formalized, but also continuing education should be
considered a key element in the program design and
maintenance.
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3843.2. Alcohol Ablation for Ventricular Arrhythmias
3.2.1. Background
When catheter-based ablation techniques to control VT
using endocardial and epicardial techniques fail to resolve
an intractable VT focus, a controlled infarction of the VT
circuit may be feasible with alcohol injection into an epi-
cardial coronary branch that supplies the region of interest on
electrophysiological mapping (165). Once a potential branch
is identiﬁed, the injection of iced saline or transient balloon
occlusion of the vessel is performed to observe whether the
arrhythmia terminates. Multiple branches may be tested
before VT termination is achieved. If such a vessel is iden-
tiﬁed, alcohol injection then is used to produce a controlled
infarction within the VT circuit. In 1 series, the method
was reported successful in 56% of the patients attempted
(166). The need for this approach has been estimated to be
very low at about 1% to 2% of VT ablation cases (167).
3.2.2. Criteria for Competency
Given the highly specialized setting where this procedure
is being attempted, only those in a tertiary center with
experience in both coronary intervention and electrophys-
iology studies should consider performing these proce-
dures. There are no established guidelines, and only case
reports and very small series have been reported. Operators
must meet established criteria for routine competency in
this infrequently performed procedure, and should be
knowledgeable and capable of describing the risks and
beneﬁts of this procedure versus other clinical choices.
Alcohol ablation for VT should always be performed in the
presence of the electrophysiologist who performed the
mapping and the electrophysiology ablation procedure.
The alcohol ablation procedure should be performed under
continuous direct electrophysiological guidance. Prospec-
tive and retrospective catheterization laboratory review of
such cases should be routinely undertaken, and at times,
institutional review board approval should be sought for
unusual situations. Although the committee acknowledges
these procedures are being occasionally done in very
controlled settings, monitoring these “orphan” procedures
necessarily requires a robust quality assurance program to
ensure patient safety and to approve operator competence.
Institutional board review approval is a requisite.
3.3. Coronary Artery Fistula Closure
3.3.1. Background
The vast majority of coronary ﬁstulae are congenital in
nature, though iatrogenic ﬁstulae have been reported after
PCI for total occlusions, after septal myectomy for
HOCM and following right heart biopsies of the inter-
ventricular septum. Congenital ﬁstulae can arise from
either coronary and generally (but not always) drain into
right heart structures. Large ﬁstulae carry a risk for coro-
nary steal and myocardial ischemia and/or infarction.Rarely dissection, rupture, and endarteritis have been re-
ported. Small ﬁstulae may increase in size over time. Most
coronary ﬁstulae are detected as incidental ﬁndings during
coronary angiography and are of no consequence.
Auscultation of large ﬁstulae reveals a continuous murmur.
Closure of large ﬁstulae has been achieved most often with
coils, though vascular plugs and covered stents may be used
when appropriate and feasible. The 2008 ACC/AHA
Guidelines for Adults with Congenital Heart Disease
(168) recommend that all symptomatic coronary ﬁstulae
should be intervened upon, but only large, audible ﬁstula
should be occluded if no symptoms. It is recognized that
there are no clear deﬁnitions of symptoms related to these
ﬁstulae, unless there is evidence for a volume overload or
demonstrable myocardial ischemia.
3.3.2. Criteria for Competency
3.3.2.1. OPERATOR COMPETENCY
Patient Care: As most patients do not need intervention for
incidental coronary ﬁstulae, optimal patient care requires
the operator be able to identify those that require closure
and understand how to best assess whether the lesion has
signiﬁcance. Surgical consultation should be included in
the evaluation to ensure the appropriate approach is being
considered. If a vascular interventional radiologist has
experience in vascular occlusion, consultation with him/her
should be part of good patient care.
Medical Knowledge and Procedural Volume: The operator
should have a thorough understanding of the cause and
anatomic features of any coronary ﬁstula of concern.
Delineation of the course of the ﬁstula is critical to
deciding if any percutaneous approach is feasible. The
operator must be comfortable with coronary intervention
and understand how to use vascular coils, plugs, and
covered stents, depending on what is required. The
procedures should only be done in centers that have
a particular interest in such interventions. Because of the
rarity of these procedures, a team approach with inter-
ventional radiology and surgery should be considered
optimal when the operator is gaining experience. Although
the SCAI training director’s survey suggested a compe-
tency threshold of 10 procedures for cardiovascular fellows
(164), this procedure is so uncommon and sporadic that it
would be unlikely that such a threshold is achievable even
in large programs. The onus once again falls on the cre-
dentialing and quality assurance oversight committees to
review all of these procedures done at any institution.
Practice-Based Learning: The need for input from
physicians outside the interventional cardiac catheteriza-
tion laboratory mandates that patients proposed for this
procedure be presented at a forum where the pros and cons
of catheter-based and surgical-based options are presented.
Various approaches should be discussed in the context of
the group experience and the available literature. Atten-
dance at national or regional meetings to improve the skill
set need should be encouraged.
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385Interpersonal and Communication Skills: Patients and
staff should have a thorough understanding of the proce-
dure. Communication with patients’ families and referring
physicians is vital in case an adverse outcome should result.
Operators must be able to work with consultants to arrive
at the appropriate decision making.
Professionalism: Operators should be able to accept the
advice of colleagues from surgery and radiology regarding
the best approach for coronary ﬁstula closure. Team
members should be respected for their contributions.
Systems-Based Practice: As with other structural heart
disease conditions, there must be a strong commitment
from the facility administration to encourage and support
a program that provides unique care offered at few other
places. Communication of the ability to perform these
procedures should be known throughout the respective
health system. An effort should be made by the principle
faculty and operators in the structural heart disease
program to educate physicians in the hospital network as to
when the procedure is required. Outcome data should be
presented periodically so that physicians and other
healthcare providers understand the risks and anticipated
results from the procedure.
3.3.2.2. STAFF COMPETENCY
As with all coronary procedures the vital core competencies
described must be an integral part of the expectation from
staff as well as operators in the cardiac catheterization
laboratory. Staff should be informed of procedural
requirements and educated about the use of each of the
interventional devices that is anticipated to be required.
They should be an integral part of the process. They should
be educated as to the complications that might occur, so as
to best alert the operator at the earliest time when
a potential untoward event appears imminent.3.4. Summary of Key Recommendations
Regarding “Other Coronary Interventions”
Multidisciplinary Approach
 Given that coronary interventions in patients with
hypertrophic cardiomyopathy, ventricular tachycardia
and coronary ﬁstulae are rare, a team approach including
coronary interventionalists, cardiothoracic surgeons, and
cardiothoracic anesthesiologists is important for optimal
results. Dedicated personnel should be identiﬁed,
and a regular review of program activity and results
documented.
Institutional Requirements
 These procedures should only be done in institutions
with a strong commitment to provide all of the neces-
sary equipment and staff support required to ensure
these rare and complex procedures can be done safely
and with a high degree of success.Operator Competence
 The ACGME Core Competency Structure pertaining
to medical knowledge; patient care and procedures;
practice-based learning; systems-based practice; inter-
personal and communication skills; and professionalism
are outlined above for each procedure. Although there
are no established minimal volume numbers for these
procedures, it is suggested for HOCM alcohol ablation
that the ﬁrst 5 procedures be proctored and that
maintenance of skills generally requires the performance
of at least 5 procedures per year.
The Critical Importance of the
Quality Assurance Program
 All of the issues outlined in regard to the quality
assurance (QA) program for routine PCI procedures
apply to the performance of these procedures. In addi-
tion, however, given the rarity of the procedures, it is
recommended that all coronary interventions for
HOCM, coronary ﬁstula, and VT be reviewed by the
multidisciplinary team and the institutional QA process.
These processes must be functioning and active to
provide appropriate oversight if operators are to perform
these uncommon coronary procedures in a safe and
monitored environment.President and Staff
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PCI percutaneous coronary intervention
PPCI primary percutaneous coronary intervention
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QI quality improvement
SCAI Society for Cardiovascular Angiography and
Interventions
STEMI ST-elevation myocardial infarction
VT ventricular tachycardia
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